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SUMMARY 
The cancer burden is rising globally, which exerts a severe impact on both the cancer 
patients and society. Cancer metastasis is the major cause of cancer mortality and accounts 
for about 90% of cancer deaths. Cancer metastasis develops through a complex multistep 
process, including dysregulated gene expression changes. These changes are mainly caused 
by somatic genetic alterations, epigenetic changes, and binding of trans-acting modulators 
including miRNAs [1, 2]. It is estimated that miRNAs regulate at least 60% of the genes 
in the human genome [3]. The defects in miRNA expression regulations and target sites 
are frequently observed in cancer metastasis [4, 5].  
miRNAs can affect multiple aspects of cancer metastasis including epithelial to 
mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET). miR-200 
family of miRNAs have been previously implicated to be important in the regulation of 
EMT/MET in multiple types of cancer [6, 7]. miR-205, a miRNA that is sequentially 
divergent from miR-200 family, has been shown to induce MET in kidney cancer [8]. 
Given that even a single nucleotide substitution within the seed region of miRNAs can 
dramatically change the spectrum of regulated mRNA target genes, it is remarkable that 
miR-205 can regulate the MET process similarly to the miR-200 family members [9]. To 
better understand the molecular mechanisms of how sequentially divergent miRNAs could 
bring about similar morphological changes characteristic of MET, we conducted the 
studies in Chapter 2. We present evidence that miR-205 and the miR-200 family of 
miRNAs coordinately induce MET in mesenchymal-like ovarian cancer cells by affecting 
both direct and indirect changes in the expression of genes. We demonstrate that the 
 xvii 
majority of changes in gene expression commonly induced by ectopic over-expression of 
the sequentially divergent miRNAs are the result of indirect regulatory controls, 
specifically in the changes in expression of EMT/MET-associated genes. Collectively, our 
findings suggest that the regulation of EMT/MET associated genes by miR-205 is the result 
of convergent evolution facilitated by the relatively recent clustering of miR-205 with 
members of the miR-200 family on human chromosome 1 approximately 80 MYA.  
Like gene expression regulation, miRNA-mediated regulation is often cancer/cell-
type specific. To better understand the molecular mechanisms underlying this specificity, 
we examined the molecular and phenotypic responses of three mesenchymal-like cancer 
cell lines (two ovarian/one prostate) to ectopic over-expression of three sequentially 
divergent miRNAs previously implicated in the EMT/MET processes. In Chapter 3, we 
demonstrate the variability of the sequentially divergent miRNAs in inducing MET in 
ovarian and prostate cancer cells. We report that the ability of these sequentially divergent 
miRNAs to induce MET in these cells is found to be associated with inherent differences 
in the starting molecular profiles of the untreated cancer cells, as well as, variability in 
trans-regulatory controls modulating the expression of genes targeted by the individual 
miRNAs. Our results help support the view that miRNAs have significant potential as 
cancer therapeutic agents. 
miRNAs can regulate their target gene expression through different mechanisms, 
including mRNA degradation and/or translational inhibition [10]. As a result, the miRNA 
targets can be translationally repressed with or without a corresponding decrease in mRNA 
abundance, or the miRNA targets can degrade mRNAs with or without a corresponding 
protein reduction. In order to understand these mRNA and protein non-correlated changes 
 xviii 
and contributions of miRNAs during ovarian cancer development, we integrated global 
miRNA and mRNA expression microarray data with proteomics data of the discrete tumor 
samples collected from the ovary and from the omentum of the same ovarian cancer patient. 
In Chapter 4, we present the miRNA mediated non-correlated changes between mRNA and 
protein levels. Our results prove that the overall correlation between changes in levels of 
mRNA and protein is low (r=0.38) and the majority of changes are on the protein level 
with no corresponding changes on their mRNA level. We provide computational and 
experimental evidence that a significant fraction of changes between mRNA and protein 
levels are mediated by miRNAs. Our findings provide an example of the contribution of 




CHAPTER 1.    INTRODUCTION 
Cancer is a leading cause of death worldwide. According to the latest global data, the 
cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths 
in 2018. Most cancer deaths are caused by cancer metastasis, not the primary tumor. It is 
estimated that metastasis is responsible for about 90% of cancer deaths [11]. 
Metastasis occurs through a multi-step process known as the invasion-metastasis 
cascade that includes the dissemination of cancer cells from primary tumors and the 
subsequent seeding of new tumor colonies in distant organs [12-14]. The dissemination 
enables malignant tumor cells to acquire certain traits that allow them to leave the primary 
site and travel through the lymphatic and hematogenous vessels to the distant metastatic 
site. The biological process that gives rise to these steps is termed "epithelial-mesenchymal 
transition" (EMT). During EMT, cancer cells lose their epithelial properties and gain 
mesenchymal features [12, 14]. The EMT process modifies the adhesion molecules 
expressed by the cell, induces growth arrest, and increases resistance to apoptosis, allowing 
the cells to adopt a migratory and invasive behavior [15-17]. In order to allow growth once 
cancer cells arrive at the distant metastatic site, the cancer cells undergo mesenchymal-to-
epithelial transition (MET) to regain a proliferative state and facilitate the formation of 
metastatic tumors at distant organs [18]. EMT and MET form the initiation and completion 
of the invasion-metastasis cascade [19].  
Metastasis can be regulated by a complex network of interconnected signaling 
pathways, transcription factors, and post-transcriptional factors [20]. Signaling pathways 
include transforming growth factor-β (TGF-β), epidermal growth factor (EGF), insulin-
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like growth factor (IGF), fibroblast growth factor (FGF), vascular endothelial growth factor 
(VEGF), WNT, and NOTCH pathway [21-25]. These pathways ultimately stimulate 
transcriptional factors, such as zinc finger E-Box binding homeobox (ZEB1 and ZEB2), 
snail family transcriptional repressor (SNAI1 and SNAI2), and twist helix-loop-helix 
transcription factor (TWIST1 and TWIST2) [26-28]. Eventually, these transcription factors 
dynamically regulate the expression of biomarker genes of metastasis, such as E-cadherin 
and N-cadherin, which facilitates the metastasis process. In addition to transcriptional level 
regulation, metastasis can also be regulated on a post-transcriptional level through 
regulatory RNAs, including microRNAs [29, 30]. 
MicroRNAs (miRNAs) are small (22-25 nucleotides long) noncoding RNA 
molecules that have been shown to be the important post-transcriptional regulators of gene 
expression [31]. To date, over 2,500 potential human miRNAs have been recorded in 
miRBase v22 and their number is increasing rapidly [32]. miRNAs are typically 
transcribed by RNA polymerase II (Pol II) in the nucleus to generate the large primary 
transcripts (pri-miRNA). The initial processing of the primary transcripts is mediated by 
Drosha-DiGeorge syndrome critical region gene 8 (DGCR8) complex that generates a pre-
miRNA that is about 70 nucleotides in length. This pre-miRNA transcript is transported 
into  the cytoplasm by the nuclear export factor, exportin 5, and further processed by the 
cytoplasmic RNase III Dicer to form the miRNA duplexes. Dicer, TAR RNA-binding 
protein (TRBP), and Argonaute (AGO) mediate the processing of miRNA duplexes and 
the assembling of the RNA-induced silencing complex (RISC) [33]. Within this complex, 
one strand of the miRNA duplex is removed, resulting in a single stranded miRNA. RISC 
guides the miRNA to bind to target complementary regions (typically 3’-UTR region) of 
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mRNA transcripts through base pairing. miRNA target recognition is primarily determined 
by pairing of the highly conserved miRNA seed sequence (nucleotides 2-8 of the miRNA) 
to complementary sites in target mRNAs [34, 35]. Depending on the complementation 
between the miRNA and target mRNA sequences, miRNAs can generally regulate the gene 
expression of the mRNA transcript in two ways. When there is a near-perfect 
complementary match between the miRNA and target mRNA sequence, miRNA degrades 
the target mRNA transcript. When there is a partial complementary match between the 
miRNA and the target mRNA sequence, the miRNA inhibits the target mRNA translation 
[36].  
Many miRNAs have been shown to be involved in metastasis, including the miR-
200 family of miRNAs. miR-200 family members have been reported to facilitate cancer 
metastasis by inducing MET in multiple types of cancer [37, 38]. The miR-200 family of 
miRNAs contains five miRNAs that can be separated into two functional groups based on 
their seed sequences. Functional group I consists of miR-200b, miR-200c, and miR-429. 
Functional group II consists of miR-141 and miR-200a. The seed sequences of these two 
functional groups only differ by one nucleotide: AAUACUG for group I and AACACUG 
for group II. Even though there are variations in molecular response and chemotherapy 
drug sensitivity between the two functional groups of miR-200 family members, all five 
members of miR-200 family are able to induce MET in ovarian cancer [7].  
Given that even a single nucleotide substitution within the highly conserved seed 
region of miRNAs can dramatically change the spectrum of regulated mRNA target genes 
[9], it is remarkable that families of miRNAs sequentially divergent from one another can 
similarly regulate the EMT/MET process in a diversity of cancer cells. For example, miR-
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205, although sequentially highly divergent from members of the miR-200 family, has been 
reported to display a similar ability to induce MET in mesenchymal-like lung [39] and 
prostate [40] cancer cells. To better understand the molecular mechanisms of how 
sequentially divergent miRNAs could bring about  similar morphological changes 
characteristic of MET, we conducted the studies in Chapter 2. We present evidence that 
helps explain how sequentially divergent miRNAs (miR-205 and miR-200 family 
members) are able to induce MET in ovarian cancer HEY cells. We first demonstrate that 
miR-205 and the miR-200 family of miRNAs both induce MET in mesenchymal-like 
ovarian cancer cells by affecting both direct and indirect changes in the expression of 
genes. We next demonstrate that the majority of changes in gene expression commonly 
induced by ectopic over-expression of the miR-200 family of miRNAs and miR-205 are 
the result of indirect regulatory controls, specifically in the changes in expression of 
EMT/MET-associated genes. While only two direct targets of these miRNAs (ZEB1 and 
WNT5A) are commonly down regulated in response to over expression of miR-205 and/or 
the miR-200 family of miRNAs, down regulation of these genes alone or in combination 
only partially recapitulated the changes induced by the miRNAs. This indicates an auxiliary 
contribution of other direct and/or indirect regulatory changes induced in common or 
individually by the miRNAs. We go on to provide evidence that regulation of EMT/MET 
associated genes by miR-205 is the result of convergent evolution brought about by a 
translocation event linking miR-205 with members of the miR-200 family on human 
chromosome 1 approximately 80 MYA. 
Individual miRNAs can target hundreds or thousands of mRNAs based on sequence 
complementarity, but a substantial fraction of these predicted interactions may depend on 
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specific cellular context. Recent studies have demonstrated that the overexpression of 
specific miRNAs has the ability to induce MET in a variety of cancer cells [41-44]. 
Interestingly, the ability of individual miRNAs to induce MET when over-expressed in 
cancer cells is often cancer/cell-type specific. To better understand the molecular processes 
underlying this specificity, we examined the molecular and phenotypic responses of three 
mesenchymal-like cancer cell lines (two ovarian/one prostate) to ectopic over-expression 
of three sequentially divergent miRNAs (miR-203a, miR-205, and miR-429) previously 
implicated in the EMT/MET processes [45, 46]. In Chapter 3, we demonstrate that the 
overexpression of miR-205 induces a morphological change to a more rounded/cuboidal 
phenotype consistent with MET in the two OC cells (HEY and SKOV3) but not in prostate 
cancer cells (PC3) relative to negative controls. In contrast, miR-203a induces 
morphological changes characteristic of MET in PC3 cells but not in the HEY and SKOV3 
cells while miR-429 induces morphological changes characteristics of MET in all three of 
the cell lines. We report that the ability of these sequentially divergent miRNAs to induce 
MET in these cells is found to be associated with inherent differences in the starting 
molecular profiles of the untreated cancer cells, as well as, variability in trans-regulatory 
controls modulating the expression of genes targeted by the individual miRNAs. Our 
results help support the view that miRNAs have significant potential as cancer therapeutic 
agents. 
The central dogma of biology defines the flow of genetic information within a 
biological system, as “DNA makes RNA and RNA makes protein” [47]. The nucleotide 
sequence of a gene determines the sequence of its mRNA product and the mRNA sequence 
determines the amino acid sequence of the resulting protein. As mRNA is ultimately 
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translated into protein, it is often assumed that changes on the mRNA level are correlated 
with changes on the protein level; however, the correlation between mRNA and protein 
abundances in the cell has been reported to be notoriously poor [48]. Systematic studies 
quantifying transcripts and proteins at genomic scales revealed the importance of multiple 
processes beyond transcript concentration that contribute to establishing the expression 
level of a protein, including protein synthesis delay, protein half-life, and translation rate 
modulation through the binding of non-coding RNAs including miRNAs [49-51]. miRNAs 
can regulate its target gene expression through different mechanisms, including mRNA 
degradation and/or translational inhibition [52]. As a result, the miRNA targets can be 
translationally repressed with or without a corresponding decrease in mRNA abundance, 
or the miRNA targets degrade mRNA with or without a corresponding protein reduction.  
Over the last two decades, high-throughput technologies have been developed to 
support the large-scale quantitative analysis of transcriptomes and proteomes, which 
enables the systematic comparison of the mRNA and protein changes in parallel. In order 
to understand the mRNA and protein non-correlated changes and contributions of miRNAs 
during ovarian cancer development, we integrated global miRNA and mRNA expression 
microarray data with proteomics data of the discrete tumor samples collected from the 
ovary and from the omentum of the same ovarian cancer patient. In Chapter 4, we present 
evidence that the majority of changes in gene expression between tumor samples collected 
from the ovary and omentum of the same patient occur at the post-transcriptional level. We 
first proved that the overall correlation between global changes in levels of mRNAs and 
their encoding proteins is low (r=0.38). We next verified that the majority of differences 
are on the protein level with no corresponding change on the mRNA level. More 
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importantly, we revealed the limitation of making functional predictions from the 
differentially expressed genes from RNA profiling alone. We further validated that a 
significant fraction of the discordance in changes on the RNA and protein levels between 
our samples are mediated by miRNAs. Our results provide an example of the contribution 







CHAPTER 2. SEQUENTIALLY DIVERGENT MIRNAS 
CONVERGE TO INDUCE MESENCHYMAL-TO-EPITHELIAL 
TRANSITION IN OVARIAN CANCER CELLS THROUGH DIRECT 
AND INDIRECT REGULATORY CONTROLS 
2.1 Abstract 
Background: Epithelial-to-mesenchymal transition (EMT) has been shown to be 
similarly regulated by multiple miRNAs, some displaying little or no sequence identity. 
While alternate models have been proposed to explain the functional convergence of 
sequentially divergent miRNAs, little experimental evidence exists to elucidate the 
underlying mechanisms involved.   
Methods: Representative members of the miR-200 family of miRNAs and the 
sequentially divergent miR-205 miRNA were independently overexpressed in 
mesenchymal-like ovarian cancer (OC) cells resulting in mesenchymal-to-epithelial 
transition (MET). Gene expression analyses combined with target gene prediction and 
siRNA knockout experiments identified genes directly or indirectly regulated by each 
miRNA.  
Results: The sequentially divergent miR-205 and the miR-200 family of miRNAs 
coordinately induce MET in mesenchymal-like OC cells by affecting both direct and 
indirect changes in the expression of genes previously associated with EMT/MET. Only 
two direct targets of these miRNAs (ZEB 1 and WNT5A) are commonly down-regulated in 
response to over-expression of miR-205 and/or the miR-200 family of miRNAs. Down-
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regulation of these genes, alone or in combination, only partially recapitulates the changes 
induced by the miRNAs indicating an auxiliary contribution of direct and/or indirect 
changes regulated by the miRNAs. Combined gene expression analyses and phylogenetic 
comparisons support an evolutionarily more recent involvement of miR-205 in the 
EMT/MET process.  
Conclusions: MiR-205 and the miR-200 family of miRNAs coordinately induce 
MET in mesenchymal-like OC cells by inducing both direct and indirect regulatory 
changes in the expression of EMT/MET associated genes. Regulation of EMT/MET 
associated genes by the sequentially divergent miR-205 is the likely result of convergent 
evolution facilitated by chromosomal clustering of miR-205 with members of the miR-200 
family ~ 80 MYA.  
 
2.2 Introduction 
Epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition 
(MET) are reciprocal molecular processes essential in early embryonic development that 
have been co-opted by cancer cells to facilitate tumor metastasis [53]. Recent studies have 
demonstrated that both EMT and MET can be induced by modulations in cellular levels of 
microRNAs (miRNAs), a well-studied class of small regulatory RNAs [54]. Our laboratory 
has been particularly interested in the ability of members of the sequentially homologous 
miR-200 family of miRNAs to induce MET when ectopically overexpressed in 
mesenchymal-like ovarian cancer (OC) cells [7]. Given that even a single nucleotide 
substitution within the highly conserved seed region of miRNAs can dramatically change 
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the spectrum of regulated mRNA target genes [9], it is remarkable that families of miRNAs 
sequentially divergent from one another can similarly regulate the EMT/MET process in a 
diversity of cancer cells. For example, miR-205, although sequentially highly divergent 
from members of the miR-200 family, has been reported to display a similar ability to 
induce MET in mesenchymal-like lung [39] and prostate [40] cancer cells. We report here 
that although miR-205 has little to no sequence homology with members of the miR-200 
family of miRNAs, it induces morphological transitions in mesenchymal OC cells that are 
morphologically indistinguishable from those induced by members of the sequentially 
divergent miR-200 family. We show that miR-205 and the miR-200 family of miRNAs 
coordinately induce MET in mesenchymal-like OC cells by affecting both direct and 
indirect changes in the expression of genes previously associated with EMT/MET. While 
two direct targets of these miRNAs (ZEB 1 and WNT5A) are commonly down-regulated in 
response to over-expression of miR-205 and/or the miR-200 family of miRNAs, down-
regulation of these genes alone or in combination only partially recapitulates the changes 
induced by the miRNAs indicating an auxiliary contribution of other direct and/or indirect 
regulatory changes induced in common or individually by the miRNAs. Finally, evidence 
is presented indicating that regulation of EMT/MET associated genes in humans by miR-
205 is the result of convergent evolution facilitated by the clustering of miR-205 with 
members of the miR-200 family on chromosome 1  80 MYA [55].  
 
2.3 Materials and Methods 
2.3.1 Cell culture and transfection 
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The HEY cell line was kindly provided by Gordon Mills, Department of Molecular 
Therapeutics, University of Texas, MD Anderson Cancer Center. Cells were cultured in 
RPMI 1640 (Mediatech, Manassas, VA) supplemented with 10% FBS (Fetal Bovine 
Serum; Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-antimycotic solution 
(Mediatech-Cellgro). 1 × 105 cells were seeded per well in 6-well plates. For miRNA 
transfection, cells at exponential phase of growth were transfected with 33 nM Pre-miR 
miRNA Precursors (Life Technologies, Carlsbad, CA) using Lipofectamine 2000 (Life 
Technologies). Pre-miR miRNA Precursor Negative was used as negative control. For 
siRNA transfection, cells at exponential phase of growth were transfected with 33 nM 
Silencer Select (Life Technologies) using Lipofectamine 2000 (Life Technologies). 
Silencer Select Negative Control siRNA was used as a negative control. Cells were allowed 
to grow for 48 h before RNA extraction. 
 
2.3.2 Microarray analysis 
Cells were harvested at 48 h after transfection and RNA extracted and subjected to 
microarray analysis (Affymetrix, U133 Plus 2; Santa Clara, CA) as previously described 
[56]. Robust Microarray Averaging (RMA) was used for normalization of microarray 
signal and summarization using the Affymetrix Expression Console Software (Version 
1.4). Statistical analysis of the expression data was carried out using the limma package 
[57] executed in R. Differentially expressed mRNAs were identified through fold change 
and FDR adjusted p-value calculated using moderated t-test. 
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2.3.3 Gene set similarity measurement 
The cosine similarity index was used to determine the similarity between two sets of genes 
[58]. 
 
2.3.4 miRNA target prediction 
Prediction algorithms were downloaded and implemented (miRanda [59] - 
(www.microrna.org), miRDB [60] - (http://mirdb.org/download.html), and TargetScan 
[61] - (http://www.targetscan.org/vert_72/) according to the recommended procedures.  
 
2.3.5 Image analysis 
Morphological changes were monitored using an Olympus IX51 microscope (Olympus 
Optical, Melville, NY) and quantified using CellProfiler cell-imaging software (2.1.0) [62]. 
 
2.3.6 Real-time PCR 
Total RNA was extracted from cells using the RNeasy Mini Kit (RNeasy, Qiagen, 
Germantown, MD). Four micrograms of RNA were reversed transcribed into cDNA using 
the Superscript III First-Strand Synthesis System (Life Technologies) according to the 
manufacturer’s instructions. Real-time PCR was performed using TaqMan Real-Time PCR 
Master Mixes (Life Technologies) on a CFX96 Real-Time System (Bio-Rad, Hercules, 
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CA). Expression values were normalized using GAPDH as a reference gene. 
Normalization and fold-change were calculated using the ∆∆Ct method. 
 
2.3.7 Western Blot 
The total protein concentration of the supernatant was determined using a protein assay 
reagent kit (Bio-Rad). To the lysates, equal volumes of 2X Laemmli sample buffer were 
added and the samples were heated to 90 °C for 5 minutes. Equal amounts of proteins were 
separated by 4–20% gradient precast TGX gel (Bio-Rad) and transferred to nitrocellulose 
membranes (Bio-Rad). Membranes were blocked with 5% nonfat dry milk in 10 mM Tris 
buffered saline. After blocking, the membranes were probed with the primary antibody 
overnight at 4 °C with gentle shaking. Antibodies used are against Zinc Finger E-Box 
Binding Homeobox 1 (ZEB1 antibody, Cat # 3396, Cell Signaling Technology, Danvers, 
MA), Wnt Family Member 5A (WNT5A antibody, Cat # 2392, Cell Signaling 
Technology), and Beta-actin (ACTB antibody Cat # 5441, Sigma, St. Louis, MO). After 
incubation with the corresponding anti-mouse- or anti-rabbit-horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology, Inc., Dallas, TX), the 
Western blots for specific proteins were detected using an enhanced chemiluminescence 
(ECL) kit (Life Technologies) and images were developed by Amersham Imager 600 (GE 




2.4.1 miR-205 overexpression induces morphological changes characteristic of MET 
indistinguishable from those induced by the sequentially divergent miR-200 family 
of miRNAs. 
We have previously reported that ectopic overexpression of miR-200 family members in 
mesenchymal-like OC cells results in the induction of morphological and molecular 
changes characteristic of MET [41, 63, 64]. We were interested in determining if ectopic 
overexpression of miR-205 could induce similar changes despite being sequentially highly 
divergent from miR-200 family members (Figure 2.1 B). Towards this end, we conducted 
a series of experiments where two representative members of the miR-200 family (miR-
141 and miR-200b) and miR-205 were individually ectopically over-expressed in HEY 
cells. The results presented in Figure 2.1 A demonstrate that over expression of miR-205 
in HEY cells does induce changes in OC HEY cells characteristic of MET that are visually 
indistinguishable from those induced by the two representative members of the miR-200 
family. Cell eccentricity analyses confirm that there is no statistically significant difference 
between the morphological changes induced by over expression of miR-205 and the two 
representative members of miR-200 family (Figure 2.1 C). Coordinated increases in the 
expression of representative epithelial biomarkers (KRT7, KRT8, KRT18) and decreases 
in the expression of mesenchymal biomarkers (VIM, FN1, ZEB1, ZEB2) are consistent 
with mesenchymal-to-epithelial transitions in response to over expression of each of the 
miRNAs (Figure 2.1 D).  
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Figure 2.1. miR-205 overexpression induces morphological changes characteristic of 
MET indistinguishable from those induced by the sequentially divergent miR-200 
family of miRNAs. (A) Representative microscopic images of HEY cells 48 h post 
transfection with miRNAs. (Scale bars, 100 µm). (B) Sequence alignments of miR-
141, miR-200b, and miR-205. Seed regions are colored in red. Differences in seed 
region of miRNAs relative to miR-200b are underlined. (C) The accumulation of 
rounded epithelial-like cells occurred in miR-141/200b/205 transfected cells 48 h post 
transfection. (cell eccentricity: a score of 0 = circular shape, a score of 1 = linear 
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shape; asterisk = p-value < 0.05). Significance of differences is evaluated using 
Student’s t-test. (D) Gene expression of representative epithelial and mesenchymal 
biomarkers post 48 h transfection with miRNAs evaluated by microarray profiling 
analyses (compared to miR-NC, p-value < 0.05). 
 
2.4.2 The majority of changes in gene expression commonly induced by ectopic over-
expression of the miR-200 family miRNAs and miR-205 are the result of indirect 
regulatory controls. 
In an effort to better understand the molecular changes mediated by over expression of 
miR-200 family (miR-141 and miR-200b) and miR-205 miRNAs relative to controls, we 
conducted microarray gene expression analyses (Affymetrix, U133 Plus 2.0 Array; Table 
A.1) as previously described [65]. We focused initially on changes in gene (mRNA) 
expression induced in common by ectopic over-expression of the two representative 
members of the miR-200 family. Of the 6416 genes significantly differentially expressed 
in response to ectopic over-expression of the miR-200 family members, 1994 genes were 
induced in common (Figure 2.2 A). The cosine similarity index of differentially expressed 
genes between the miR-200 family members is 0.51. This value of similarity was increased 
when comparing differentially expressed genes between miR-205 and miR-141/miR-200b. 
3453 genes were induced in common between miR-205 and miR-141, with a similarity 
index of 0.65 (Figure 2.2 B), while 2197 genes were induced in common between miR-
205 and miR-200b, with a similarity index of 0.59 (Figure 2.2 C). Overall, 91.3% 
(1821/1994) of the genes differentially expressed by ectopic over-expression of both miR-
200 family miRNAs were also significantly differentially expressed in response to over 
expression of miR-205 (Figure 2.2 D). 
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Figure 2.2. Analysis of differentially expressed genes after transfection of miR-200 
family members (miR-141 and miR-200b) and miR-205. (A) Venn diagram showing 
the intersection of differentially expressed genes between miR-141 and miR-200b. (B) 
Venn diagram showing the intersection of differentially expressed genes between 
miR-141 and miR-205. (C) Venn diagram showing the intersection of differentially 
expressed genes between miR-200b and miR-205. (D) Venn diagram showing the 
intersection of differentially expressed genes between miR-141, miR-200b, and miR-
205. Differentially expressed genes between categories were filtered (FDR < 0.05 and 
fold change > 1.5). 
 
 The fact that the miR-200 family and miR-205 miRNAs are sequentially highly 
divergent makes it unlikely that they directly target a high proportion of the same genes. 
We confirmed this by employing three independent prediction algorithms (miRanda [59], 
miRDB [60], TargetScan [61]) to identify direct target genes of the three miRNAs analyzed 
in this study (Table A.2, Table A.3, Table A.4). For example, according to the miRanda 
miRNA target prediction algorithm [59], 3943, 4027, and 2941 genes are predicted to be 
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direct target genes of miR-141, miR-200b, and miR-205, respectively. Among these, 1440 
genes are predicted to be direct target genes of both miR-141 and miR-200b, but only 444 
out of these 1440 genes (30.8%) are predicted to be direct target genes of miR-205 (Figure 
2.3). 
 
Figure 2.3. Analysis of intersection between miRanda-predicted direct target genes of 
miR-200 family members (miR-141 and miR-200b) and miR-205. (A) Venn diagram 
showing the intersection of direct target genes between miR-141 and miR-200b. (B) 
Venn diagram showing the intersection of direct target genes between miR-141, miR-
200b, and miR-205. 
  
 Overall, our gene expression analysis, demonstrates that of the 1994 genes 
displaying a significant change in expression in response to overexpression of the miR-200 
family miRNAs, only 181 genes (9.1%) are predicted to be direct target genes of both of 
these miRNAs (Figure 2.4 A). Of the 1821 genes induced in common by the miR-200 
family miRNAs and miR-205, only 61 (3.3%) are predicted to be direct target genes of all 
of these miRNAs (Figure 2.4 B). These results indicate that the vast majority of the changes 
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in gene expression commonly induced by ectopic over-expression of the miR-200 family 
miRNAs and miR-205 are the result of indirect regulatory effects.  
 
Figure 2.4. Analysis of the intersection between differentially expressed genes and 
miRNA target genes after transfection of miR-200 family members (miR-141 and 
miR-200b) and miR-205. (A) Venn diagram showing the intersection of differentially 
expressed genes and miRanda-predicted miRNA target genes between miR-141 and 
miR-200b. (B) Venn diagram showing the intersection of differentially expressed 
genes and miRanda-predicted miRNA target genes between miR-200 family members 
(miR-141 and miR-200b) and miR-205. Differentially expressed genes between 
categories were filtered (FDR < 0.05 and fold change > 1.5). 
 
2.4.3 The majority of changes in expression of EMT/MET-associated genes commonly 
induced by ectopic overexpression of the miR-200 family miRNAs and miR-205 are 
also the result of indirect regulatory controls. 
We were next interested in determining if similar trends apply to a subset of genes 
previously identified as being directly involved in EMT/MET. For these studies, we 
focused our analysis on 84 genes that have been previously linked to the EMT/MET 
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process [66]. Thirty-eight of these 84 genes were significantly differentially expressed by 
ectopic overexpression of at least one of the miR-200 family members (miR-141 and miR-
200b) or miR-205 (Figure 2.5). Of these 38 genes, 17 (44.7%) were commonly induced by 
both members of the miR-200 family tested. Interestingly, 15 out of these 17 genes (88.2%) 
are also differentially expressed when miR-205 is included in the analysis. Of the 17 
EMT/MET genes induced in common by the miR-200 family members, only four (23.5%) 
are predicted to be direct target genes of these miRNAs. Likewise, of the 15 EMT genes 
induced in common by the miR-200 family and miR-205 miRNAs, only two (13.3%) genes 
(ZEB1 and WNT5A) are predicted to be directly targeted in common by these miRNAs 
(Figure 2.5). 
 
Figure 2.5. Analysis of the intersection between differentially expressed EMT/MET 
genes and miRNA target genes after transfection of miR-200 family members (miR-
141 and miR-200b) and miR-205. Thirty-eight EMT/MET genes were significantly 
differentially expressed by ectopic over-expression of at least one of the miR-200 
family members (miR-141 and miR-200b) or miR-205. Each circle represents a gene. 
The right half of the circle represents if the gene has been differentially expressed 
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(DE) after transfection of miR-141 (right-top), miR-200b (right-middle), or miR-205 
(right-bottom) in HEY cells after 48 h transfection. The left half of the circle 
represents if the gene is a direct target gene of miR-141 (left-top), miR-200b (left-
middle), or miR-205 (left-bottom). The white slice of the circle means either this gene 
is not differentially expressed after transfection, or this gene is not the direct target 
of the corresponding miRNA. The non-white slice of the circle means either this gene 
is differentially expressed after transfection, or this gene is the direct target of the 
corresponding miRNA. Genes highlighted in red are the EMT/MET genes that are 
differentially expressed direct target genes of both miR-200 family members (miR-
141 and miR-200b) and miR-205. 
 
2.4.4 Knockdown of ZEB1 and/or WNT5A induces intermediate morphological changes 
in HEY cells 
Of the EMT-associated genes directly targeted in common by miR-141, miR-200b and 
miR-205, only ZEB1 and WNT5A were consistently down regulated after ectopic 
overexpression of these miRNAs (Figure 2.6 A). This raises the possibility that reduced 
expression of these genes may alone be responsible for the morphological changes 
associated with over expression of the miRNAs. To test this hypothesis, we ectopically 
over-expressed siRNAs against ZEB1 and WNT5A (alone and in combination) in HEY 
cells.  While knockdown of ZEB1 and WNT5A, alone or in combination, resulted in a 
significant decrease in the expression of these genes on both the mRNA (Figure 2.6 B) and 
protein levels (Figure 2.6 C), the cell eccentricity analyses indicated a non-significant 
overall difference in cell morphology from the negative controls (Figure 2.7 A, B). 
However, detailed examination of cell images in the ZEB1/WNT5A knockdown groups 
reveals that some cells clearly exhibit a cuboidal, epithelial-like phenotype after treatment 
indicative of a partial or intermediate induction of MET (e.g., note cells circled in yellow 
in Figure 2.7 A).  
 22 
 
Figure 2.6. Analysis of ZEB1 and WNT5A expression in miRNA and siRNA 
transfected cells. (A) ZEB1 and WNT5A expression were consistently down regulated 
after transfection of the miRNAs. Asterisks represent statistically significant 
differences from the negative control group. (*p-value < 0.05) (B) Relative mRNA 
expression of ZEB1 and WNT5A as determined by qRT-PCR shows a significant 
decrease on the mRNA levels in the corresponding individual transfections and 
combined transfection groups. Asterisks represent statistically significant differences 
from the negative control group. (*p-value < 0.05) (C) Western blot analysis of ZEB1 
and WNT5A proteins both display reduced levels of protein in the corresponding 




Figure 2.7. Significant changes in HEY cell morphology characteristic of MET 
induced by miR-200 family (miR-141/miR-200b) or miR-205 over expression are 
partially recapitulated by transfection with ZEB1 and/or WNT5A siRNAs. (A) 
Representative microscopy images after 48 h transfection with ZEB1 and/or WNT5A 
siRNAs or miR-141, 200b, or 205. The representative epithelial-like cells in the ZEB1 
and/or WNT5A knockdown groups are circled in yellow. (B) Boxplots showing the 
median of cell eccentricity of ZEB1 and/or WNT5A knockdown groups is consistently 
lower than cell eccentricity of negative control group, but higher than the median of 
cell eccentricity of the miR-200 family or miR-205 over expression groups. [ns: non-
statistically significant from the negative control group; asterisks: statistically 
significant differences from the negative control group. (*p-value < 0.05)]. (C) Heat 
map of gene expression (mRNA) features representing sixteen canonical EMT 
markers of ZEB1 and/or WNT5A knockdown groups and miR-200 family or miR-
205 over expression groups. Dark blue colors represent higher expression of that gene 
in that sample. These features were summarized into an EMT phenotype score for 
each sample. Dark purple colors represent a more mesenchymal-like phenotype. 
Samples are ordered by high to low average EMT score. 
 
2.4.5 Knockdown of ZEB1 and/or WNT5A induces gene expression changes in HEY cells 
indicative of partial MET 
To determine if the apparent intermediate level of morphological changes associated with 
knockdown of ZEB1/WNT5A may be similarly reflected on the molecular level, we 
employed a previously established analytical method that assigns an EMT score based on 
relative gene expression levels of a 16 gene panel of canonical EMT genetic markers [67]. 
In order to get the expression levels of these 16 genes, we conducted microarray gene 
expression analyses (Affymetrix, U133 Plus 2.0 Array; Figure 2.7 C and Table A.5) as 
previously described [65]. Cells with higher ranked EMT scores are considered more 
mesenchymal-like while those with lower scores are considered more epithelial-like [67]. 
Consistent with the results of our morphological analyses, the ZEB1/WNT5A knockdown 
groups were found to display intermediate EMT scores between negative controls and the 
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miR-200b, miR-141, and miR-205 over-expression groups. Of the ZEB1/WNT5A 
knockdown groups in HEY cells, si-ZEB1 is associated with the lowest EMT score (4.19) 
followed by si-ZEB1-WNT5A (4.57) and si-WNT5A (4.59). Of the three miRNAs over-
expressed in HEY cells, miR-200b is associated with the lowest EMT score (2.46) followed 
by miR-141 (3.21) and miR-205 (3.97).  
 
2.4.6 miR-205 targets fewer EMT/MET associated genes than members of the miR-200 
family suggesting an evolutionarily more recent role in the EMT/MET process 
The fact that miR-205 over expression is associated with the highest EMT score of the 
miRNAs tested is correlated with the fact that miR-205 is predicted to target relatively 
fewer EMT/MET associated genes than the miR-200 family (miR-200b, miR-141) (Table 
A.6). Consider, for example, the representative EMT/MET pathway depicted in Figure 2.8.  
While miR-200b and miR-141 are predicted to directly target 30 and 28 EMT/MET 
pathway genes, respectively, miR-205 is predicted to target only 17 genes. Collectively, 
these and similar results (Table A.7) suggest that miR-205’s involvement in the EMT/MET 
process may be evolutionarily more recent than the involvement of the miR-200 family.  
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Consistent with this hypothesis, miR-200b has been shown to be involved in 
EMT/MET associated processes in the mouse [68, 69] while miR-205’s role  in mouse 
development is reported to be more limited in scope [70].  Moreover, while miR-200b and 
miR-205 are clustered together on the same chromosome in humans  (human chromosome 
1) placing them under similar regulatory control [71], miR-205 maps to a distinct 
chromosomal location (mouse  chromosome 1) from miR-200b (mouse chromosome 4) in 
mice. Collectively, these observations suggest an evolutionarily more recent involvement 
of miR-205 in the EMT/MET process possibly facilitated by a chromosomal translocation 




In principle, the induction of similar morphological changes in response to over expression 
of the sequentially divergent miR-200 family and miR-205 miRNAs may be explained by 
at least two not-mutually-exclusive hypotheses. First, if the miR-200 family and miR-205 
miRNAs bind to the same mRNA (gene) target sequence(s), it could explain their 
coordinated regulation of the same genes. This hypothesis, however, is inconsistent with a 
large body of data indicating that high-sequence complementarity between miRNA seed 
regions and mRNA target sequence is pre-requisite to miRNA regulation [72]. Moreover, 
we have previously shown that even a single nucleotide substitution within the seed region 
of miR-200 family miRNAs is sufficient to dramatically disrupt downstream regulatory 
controls [9]. Thus, the high sequence divergence between miR-205 and members of the 
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miR-200 family of miRNAs effectively precludes the possibility that they are targeting the 
same mRNA binding sites. 
 A second, more likely scenario is that many of the genes involved in the induction 
of MET in HEY cells contain duplicate yet distinct target sequences for miR-200 family 
and miR-205 miRNAs. Indeed, it is well documented that most mRNAs (genes) contain 
target sequences for more than one miRNA and are thereby subject to regulatory control 
by multiple miRNAs [73]. Although we find that only a small percentage (<3%) of genes 
significantly differentially expressed in common after ectopic over expression of miR-205 
or the miR-200 family of miRNAs (including genes previously implicated in EMT/MET) 
are predicted to be direct targets, changes in the expression of these direct targets are 
presumably the ultimate source of the subsequent regulatory changes, and many prior 
studies have confirmed the functional  importance of these direct regulatory controls [45, 
58]. Among genes previously implicated in the EMT process that we found to be 
consistently down regulated after ectopic over-expression of miR-205 or miR-200 family 
miRNAs in HEY cells, only ZEB1 and WNT5A are predicted to be direct target genes of 
these miRNAs. While siRNA-mediated knock down of ZEB1 and WNT5A, individually or 
in combination, was found to induce morphological and molecular changes characteristic 
of partial MET, it was not sufficient to recapitulate the changes induced by the miRNAs. 
This finding is consistent with an auxiliary contribution of other direct and/or indirect 
regulatory changes induced in common and/or individually by miR-205, miR-200b and 
miR-141. 
 The fact that miR-205 targets fewer EMT/MET associated genes than members of 
the miR-200 family suggests that the contribution of miR-205 to the regulation of 
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EMT/MET in humans is a more recent evolutionary event. We previously reported that 
while the seed sequence of the miR-200 family of miRNAs is highly conserved across 
vertebrate species, the genes targeted by these miRNAs are highly diverse [9]. This 
observation coupled with the finding that only a single nucleotide substitution in the target 
sequence (seed region) of miRNA-regulated genes can result in loss/gain of regulatory 
controls, led to formulation of an evolutionary model whereby individual genes may lose 
and/or acquire new miRNA control(s) over time through relatively minor changes in 
miRNA target sequence [9]. Thus, one possible explanation of the more recent contribution 
of miR-205 to EMT/MET trans-regulation is that it more recently acquired an expression 
pattern compatible with the EMT/MET process in higher vertebrates, leading to subsequent 
selection for the acquisition of miR-205 target sequences in EMT/MET associated genes 
(e.g., WNT5A, ZEB1). In this regard, it is relevant to note that while miR-200b and miR-
205 are clustered together on the same chromosome in humans (human chromosome 1) 
and display coordinated patterns of expression in apparent response to the same regulatory 
controls [71],  in the mouse, miR-205 maps to a distinct chromosomal location (mouse  
chromosome 1) from miR-200b (mouse chromosome 4) placing the two miRNAs under 






CHAPTER 3. MIRNA-MEDIATED INDUCTION OF 
MESENCHYMAL-TO-EPITHELIAL TRANSITION (MET) 
BETWEEN CANCER CELL TYPES IS SIGNIFICANTLY 
MODULATED BY INTER-CELLULAR MOLECULAR 
VARIABILITY   
3.1 Abstract 
Background: Ectopic overexpression of specific miRNAs has previously been 
reported to induce MET in a variety of cancer cells; however, the ability of individual 
miRNAs to induce MET when over-expressed in cancer cells is often cancer/cell-type 
specific. 
Methods: Three sequentially divergent miRNAs previously implicated in the 
EMT/MET process were independently overexpressed in 3 mesenchymal-like cancer cell 
lines (2 ovarian/1 prostate). The molecular and phenotypic responses in each cell line were 
examined. 
Results: The ability of these sequentially divergent miRNAs to induce MET in 
these cells was found to be associated with inherent differences in the starting molecular 
profiles of the untreated cancer cells and specifically, variability in trans-regulatory 
controls modulating the expression of genes targeted by the individual miRNAs. 
Conclusions: While our results support the view that miRNAs have significant 
potential as cancer therapeutic agents, our findings further indicate that optimal treatments 
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will likely need to be personalized with respect to the molecular profiles of the individual 
cancers being treated. 
 
3.2 Introduction 
Recent years have witnessed a dramatic increase in our appreciation of the contribution of 
microRNAs (miRNAs) to cancer onset and progression [74]. As a consequence, there has 
been growing interest in the development of miRNAs not only as diagnostic biomarkers of 
cancer but also as a promising new class of therapeutic agents. Over the last several years, 
our laboratory has focused on analysis of the molecular processes underlying the ability of 
individual miRNAs to induce mesenchymal-to-epithelial transition (MET) particularly in 
ovarian cancer [64, 75-77]. Ectopic over expression of specific miRNAs down regulated 
during epithelial-to mesenchymal transition (EMT) have previously been reported to 
induce MET in a variety of cancer cells [42-44, 75], thereby reducing metastatic potential 
and resistance to standard-of-care chemotherapies [78, 79]. Interestingly, the ability of 
individual miRNAs to induce MET when over expressed in cancer cells is often 
cancer/cell-type specific. In an effort to better understand the molecular processes 
underlying this specificity, we examined the molecular and phenotypic responses of three 
mesenchymal-like cancer cell lines (two ovarian and one prostate) to ectopic over 
expression of three sequentially divergent miRNAs previously implicated in the 
EMT/MET process [76, 80]. The ability of these sequentially divergent miRNAs to induce 
MET in these cells was found to be associated with inherent differences in the starting 
molecular profiles of the untreated cancer cells and specifically, variability in trans-
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regulatory controls modulating the expression of genes targeted by the individual miRNAs. 
While our results support the view that miRNAs have significant potential as cancer 
therapeutic agents, our findings further indicate that optimal treatments will likely need to 
be personalized with respect to the molecular profiles of the individual cancers being 
treated. 
 
3.3 Materials and Methods 
3.3.1 Cell culture and miRNA transfection 
The HEY cell line was kindly provided by Gordon Mills, Department of Molecular 
Therapeutics, University of Texas, MD Anderson Cancer Center. SK-OV-3, and PC-3 cells 
were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Cells 
were cultured in RPMI 1640 (Mediatech, Manassas, VA) supplemented with 10% FBS 
(Fetal Bovine Serum; Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-
antimycotic solution (Mediatech-Cellgro, Manassas, VA). For miRNA transfections, 
1 × 105 cells were seeded per well in 6-well plates. Cells at exponential phase of growth 
were transfected with 33 nM miRNA purchased as Pre-miR miRNA Precursors (Life 
Technologies, Carlsbad, CA) using Lipofectamine 2000 (Life Technologies) and according 
to the manufacturer’s instructions. Pre-miR miRNA Precursor Negative Control (Life 
Technologies) was used as a negative control. Cells were allowed to grow for 48 hours 
before RNA isolation. 
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3.3.2 Microarray analysis 
Un-transfected cells and the transfected cells (miR-NC, miR-203a, miR-205, and miR-429) 
were harvested, and the RNA  was extracted and subjected to microarray analysis 
(Affymetrix, U133 plus 2; Santa Clara, CA) as previously described [56]. Robust 
Microarray Averaging (RMA) was used for normalization of microarray signal and 
summarization using the Affymetrix Expression Console Software (Version 1.4). 
Statistical analysis of the expression data was carried out using the limma package executed 
in R [57]. Differentially expressed mRNAs were identified through adjusted p-value (FDR 
< 0.01) calculated using the moderated t-test. 
 
3.3.3 miRNA target prediction 
MiRNA target predictions (based on mirSVR) were downloaded from microRNA.org 
(August 2010 release) [59]. The mirSVR score refers to targets of microRNAs with 
scores obtained from the support vector regression algorithm. To reduce the occurrence 
of false positives, only predicted targets with a mirSVR score less than −0.1 were 
considered. 
 
3.3.4 Image analysis 
Morphological changes were monitored using an Olympus IX51 microscope (Olympus 
Optical, Melville, NY) and quantified using CellProfiler cell-imaging software (2.1.0) [62]. 
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3.3.5 Sequence analysis of miRNA binding sites in SK-OV-3 and PC-3 cells 
Full methods on whole exome sequencing (WES) sequencing and variant calling are 
described by Ogan et al. [81]. Briefly, 37Mb of coding region for each cell line were 
captured by the Agilent SureSelect All Exon v1.0 kit (Agilent, Santa Clara, CA), sequenced 
using the Illumina Genome Analyzer IIx instrument (Illumina, San Diego, CA), bases 
called via standard BWA-GATK pipeline, and followed by quality filtering as described 
by Ogan et al [81]. The processed exome sequencing file was downloaded from CellMiner 
Database (Version 2.1) [82]. 
 Genome coordinates (hg19) of miR-203a, miR-205, and miR-429 target gene 
microRNA binding sequences (MBSs) were downloaded from microRNA.org [83]. To 
identify WES variants that were overlapping with these microRNA sites, we used 
customized python scripts. 
 
3.3.6 Transcriptional repressor selection 
Human transcription factor (TF)-target regulatory relationships were downloaded from the 
Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining 
(TRRUST) database [84].  
 
3.3.7 EMT phenotype score calculation 
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The EMT score is generated by addition of thirteen mesenchymal-associated gene 
expression values and a corresponding subtraction of three epithelial-associated gene 
expression values to give a summary score of the EMT phenotype [67]. Cells with a high 




3.4.1 The ability of miRNAs to induce morphological changes characteristic of MET is 
cancer cell line-dependent  
Mir-429, miR-205 and miR-203a have all been previously reported to induce 
morphological changes characteristic of MET when ectopically over expressed in cancer 
cells [76, 80]. To determine the influence of individual cancer cell lines/cancer types on 
this process, we ectopically over expressed each of these miRNAs in two individually 
derived ovarian cancer (OC) cell lines (HEY [85], SK-OV-3 [86]) and one prostate cancer 
(PC-3) [87] cell line. All of these cell lines display a starting elongated mesenchymal-like 
morphology but respond differently within 48 h of ectopic over expression of each of the 
three miRNAs relative to a synthetic negative control miRNA.  We quantified 
morphological differences existing between the three cell types before and after ectopic 
over expression of the three miRNAs using CellProfiler cell-imaging software (2.1.0) [88]. 
The results (Figure 3.1) indicate that un-transfected HEY cells display the most elongated, 
mesenchymal-like morphology followed by PC-3 cells and SK-OV-3 cells, which 





Figure 3.1. Comparison of morphological changes induced by over expression of the 
same suite of miRNAs (miR-203a, miR-205, and miR-429) in mesenchymal-like cells 
(HEY, SK-OV-3, and PC-3 cells). (A) Representative microscopic images (20X) of 
untransfected and transfected cells (48 h post-transfection with miRNAs; scale bars, 
50 µm; "+" = MET; "-" = no MET). (B) The accumulation of a more rounded 
epithelial-like cells occurred in miR-429/205 transfected ovarian cancer cells (HEY 
and SK-OV-3 cells) and miR-429/203a transfected prostate cancer cells (PC-3 cells) 
48 h post-transfection (cell eccentricity: a score of 0 = circular shape, a score of 
1 = linear shape). Significance of differences is evaluated using Student’s t-test. 
(compared to miR-NC, p-value < 0.05). 
  
Over expression of miR-205 induced a significant morphological change to a more 
rounded/cuboidal phenotype consistent with MET in the two OC cell lines (HEY and SK-
OV-3) but not in the prostate cancer cell line (PC-3) relative to negative controls. In 
contrast, miR-203a induces morphological changes characteristic of MET in PC-3 cells but 
not in the HEY and SK-OV-3 cells, while miR-429 induces morphological changes 
characteristic of MET in all three of the cell lines.  
 
3.4.2 Ectopic over expression of miR-203a, miR-205 and miR-429 induced both direct 
and indirect changes in gene expression in HEY, SK-OV-3 and PC-3 cells  
To explore the molecular level changes induced by ectopic over expression of each of the 
three miRNAs in the three cell lines, we extracted RNA from each of the cell lines 48 h 
after over expression of each of the three miRNAs and corresponding negative controls. 
RNA samples were collected from each of the three cell lines with three replicates of five 
treatments (miR-203a, miR-205, miR-429, miR-NC, un-transfected) for a total of 45 
samples (3 cell lines X 5 treatments X 3 replicates). Initial quality control, summarization 
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and normalization of the 45 CEL files using RMA (Robust Multiarray Average) was 
performed using the Affymetrix Expression Console as previously described [64]. The 
result was expression data for 23,031 annotated genes (Table B.1).  
 Ectopic over expression of the three miRNAs resulted in significant changes in 
gene expression in each of the cell lines (Figure 3.2A). Consistent with previous studies 
[77], we found that on average 21.3% of genes differentially expressed in response to 
miRNA over expression are predicted to be direct targets of the respective miRNAs (HEY: 
miR-203a, 491/1764 = 27.8%, miR-205,1443/11,123 = 13.0%, miR-429, 1956/9395 = 
20.8%; SK-OV-3: miR-203a, 381/882 = 43.2%, miR-205, 875/6500 = 13.5%, miR-429, 
1385/6925 = 20.0%; PC-3: miR-203a, 1846/8320 = 22.2%, miR-205, 1184/9779 = 12.1%, 
miR-429, 948/4928 = 19.2%; Figure 3.2B). The observed changes in gene expression are 
also consistent with prior evidence that the majority of changes induced by ectopic over 
expression of miRNAs are indirect, albeit initiated by changes in directly targeted genes 
[89].  
While a notable fraction of the changes in gene expression were induced in common 
in the three cell lines, the majority of differentially expressed genes were unique to each 
miRNA-cell type combination (Figure 3.2). This was most pronounced for miR-203a in 
PC-3 cells where 84.1% of differentially expressed genes did not overlap with those 
induced in HEY or SK-OV-3 cells. Interestingly, PC-3 was the only one of the three cell 
lines displaying MET in response to miR-203a over expression suggesting that at least 





Figure 3.2. Analysis of differentially expressed genes after transfection of the same 
suite of miRNAs (miR-203a, miR-205, and miR-429). (A) Venn diagram showing the 
intersection of all differentially expressed genes after over expression of miR-203a, 
miR-205, and miR-429 individually in HEY, SK-OV-3, and PC-3 cells. (B) Venn 
diagram showing the intersection of differentially expressed direct target genes after 
individual over expression of miR-203a, miR-205, and miR-429 in HEY, SK-OV-3, 
and PC-3 cells. (C) Histogram showing the percentage of the up-regulated and down-
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regulated direct target genes in differentially expressed genes after individual over 
expression of miR-203a, miR-205, and miR-429 in HEY, SK-OV-3, and PC-3 cells. 
Significantly differentially expressed genes between treatments were selected at an 
adjusted (Benjamini-Hochberg) limma p-value of 0.01. 
 
3.4.3 The unexpected response of some miRNA targeted genes may be at least partially 
explained by transcriptional override 
With the notable exception of miR-429 in SK-OV-3 cells, the majority of the miRNA 
directly targeted genes displaying significant changes in expression were down regulated 
consistent with RISC (RNA-induced silencing complex)-mediated regulation of targeted 
genes by miRNAs [90] (Figure 3.2C).  No change or up regulation of target genes after 
over expression of miRNAs has been observed previously [91, 92] and may, at least in part, 
be explained by the transcriptional override model (TOM) [93].  
 TOM postulates that the expected down regulation of target genes induced by 
elevated levels of regulating miRNAs may be masked or “overridden” by increases in 
transcriptional initiation mediated by the down regulation of repressor genes that are 
themselves targets of the same regulating miRNAs. Depending upon the strength of the 
transcriptional override (i.e., the relative strengths of miRNA and repressor gene mediated 
de-repression), TOM predicts that increases in miRNA levels may display no effect or be 
positively correlated with changes in levels of their targeted mRNAs.  
To determine if TOM may at least partially explain the differential responses of our 
cell lines to over expression of the same miRNAs, we downloaded from the TRRUST 
(Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining) 
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database [84], a list of transcription factors (TFs) thus far identified as repressors of those 
genes we observed to display no change or to be up regulated after ectopic over expression 
of the three miRNAs. From among these TFs, we further selected those repressor genes 
predicted to be targets of the same three over expressed miRNAs and that responded by 
displaying a significant down regulation in expression (see “Repressor Expression” in 
Table B.2-4). Combining this dataset with predicted gene targets [83] (of the same 
miRNAs) that displayed no change or were up regulated after miRNA ectopic over 
expression, allowed us to identify genes displaying responses consistent with TOM (Table 
3.1, Table B.2-4).  
 
Table 3.1. miRNA-mediated de-repression of repressor genes overrides the expected 
down-regulatory effects of miRNAs on their target gene expression. 













HEY 8 21 12 11 19 26 
SK-OV-3 19 36 6 9 13 21 
PC-3 19 33 12 13 13 23 
*: D, U, NC: significantly up-regulated, significantly down-regulated, non-significantly changed 
after overexpression of corresponding miRNA. 
 
In total, 105 target genes were found to display up regulation or no change in 
expression in response to miRNA over expression consistent with TOM (Table B.2-4).  For 
illustrative purposes, Figure 3.3 displays those targeted genes displaying up regulation in 
expression in response to over expression of their regulating miRNA consistent with TOM. 
For example, CDH1 (cadherin 1), a gene recognized as playing a central role in EMT/MET 
[94], is a direct target of miR-205 and yet was observed to be significantly up regulated 
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after ectopic over expression of miR-205. Interestingly, the repressor protein ZEB1, known 
to play a central role in EMT/MET [95], is also a direct target of miR-205 and a known 
regulator of CDH1 [96]. Thus, consistent with TOM, miR-205 down regulation of ZEB1 






Figure 3.3. miRNA-mediated de-repression of repressor genes (yellow triangles) may 
override the expected down-regulatory effects of miRNAs (red squares) on their 
target gene (blue squares) expression. (A) miRNA-203a, (B) miR-205, (C) miR-429 
mediated de-repression. (A) miRNA-203a, (B) miR-205, (C) miR-429 mediated de-
repression of down-regulated repressor genes overrides the expected down-
regulatory effects of miRNA, resulting in up regulation in miRNA target gene 
expression. The overridden down-regulatory effects of miRNAs on their target genes 
have been marked in red. (Direction of observed changes in gene expression in 
response to miRNA over expression indicated by arrows) 
 
3.4.4 Expression of genes previously associated with EMT/MET are significantly 
changed in response to overexpression of miR-203a, miR-205 and miR-429 in a cell-line 
specific manner  
We next focused on 84 genes previously identified as being directly or indirectly associated 
with the EMT/MET process in one or more cellular contexts (Table B.5) [97-100].  Ectopic 
 44 
over expression of each of the three miRNAs induced variable patterns of change in the 
expression of these EMT/MET associated genes across the three cell lines (Figure 3.4A).  
 In contrast to what was found for all differentially expressed as well as direct target 
genes (Figure 3.2), the majority of differentially expressed EMT/MET-associated genes 
were expressed in common in each miRNA-cell type combination (Figure 3.4). This 
change in expression pattern may be a reflection of selective enrichment in the targeting of 
EMT/MET genes by all of the miRNAs. 
 The notable exception is for genes induced by miR-203a over expression in PC-3 
where 50% of the changes in gene expression were unique to PC-3 cells. Again, it is 
interesting to note that PC-3 cells were the only one of the three cell lines displaying MET 
in response to miR-203a over expression. The observed changes in gene expression in 
EMT/MET-associated genes that were cell line/miRNA-specific in this and the other cell 




Figure 3.4. Analysis of differentially expressed EMT/MET genes after transfection of 
the same suite of miRNAs (miR-203a, miR-205, and miR-429). (A) Venn diagram 
showing the intersection of differentially expressed EMT/MET-associated genes after 
over expression of miR-203a, miR-205, and miR-429 individually in HEY, SK-OV-3, 
and PC-3 cells. (B) Venn diagram showing the intersection of differentially expressed 
directly targeted EMT/MET-associated genes after over expression of miR-203a, 
miR-205, and miR-429 individually in HEY, SK-OV-3, and PC-3 cells. Significantly 
differentially expressed EMT/MET-associated genes between treatments were 
selected at an adjusted (Benjamini-Hochberg) limma p-value of 0.01. 
 
3.4.5 The relative level of changes in cellular morphology induced by miRNA 
overexpression is correlated with changes in levels of expression of molecular biomarkers 
of EMT/MET   
To determine if differences in the level of morphological change induced by miRNA over 
expression in the three cell lines (Figure 3.1) is similarly reflected on the molecular level, 
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we employed a previously established analytical method that assigns EMT scores based on 
the relative gene expression levels of a panel of 16 canonical EMT genetic markers [67]. 
Cells with higher EMT scores are considered more mesenchymal-like while those with 
lower scores are considered more epithelial-like. Consistent with the results of our 
morphological analyses (Figure 3.1), HEY cells displayed the highest (most mesenchymal-
like) EMT score followed by PC-3 and SK-OV-3 cells, which displayed the lowest EMT 




































Figure 3.5. Comparison of EMT score changes after transfection of the same suite of 
miRNAs (miR-203a, miR-205, and miR-429) in HEY, SK-OV-3, and PC-3 cells. (A) 
Histogram showing EMT scores in untransfected and transfected (miR-NC, miR-
203a, miR-205, and miR-429) HEY, PC-3, and SK-OV-3 cells. (B-F) Heatmap of gene 




NC transfected (C), miR-203a transfected (D), miR-205 transfected (E), and miR-429 
transfected (F) HEY, PC-3, and SK-OV-3 cells.  
 
  We next computed changes in EMT scores for each of these three cell lines after 
ectopic over expression of the three miRNAs relative to negative controls.  The results 
(Figure 3.5) demonstrate that miRNA-induced changes in morphology (Figure 3.1) 
correlate well with changes in EMT scores. Over expression of miR-203a induced a 
reduction in EMT score in PC-3 cells but no change in HEY or SK-OV-3 cells. In contrast, 
over expression of miR-205 induced a reduction in EMT scores in HEY and SK-OV-3 
cells, but no change in PC-3 cells. Over expression of miR-429 induced a major change in 
EMT scores in all three of the cell lines tested.  
 Interestingly, there were significant differences among the cell lines in the 
morphological (Figure 3.1) and EMT score end points acquired in response to over 
expression of the miRNAs. For example, the end points in morphology and EMT score 
levels acquired in response to over expression of miR-205 or miR-429 in HEY cells are 
greater than in SK-OV-3 cells. Indeed, the end point responses for Hey cells are 
approximately equal to the starting point (negative control) of the SK-OV-3 cells. 
Likewise, the morphological and EMT score levels acquired in response to over expression 
of miR-203a in PC-3 cells are approximately equivalent to the starting (negative control) 
levels of SK-OV-3 cells. These results indicate that differences in the genetic background 
between each of the three cell lines not only play a significant role in determining the 
cellular response to over expression of each of the individual miRNAs but in the magnitude 
of the induced response as well.  
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3.4.6 Changes in the miRNA-induced expression patterns of EMT/MET-associated genes 
correlate with induced changes in morphology and EMT scores  
Of the 84 genes previously implicated in the EMT/MET process, some have been 
previously identified as being typically up regulated during EMT (i.e. down regulated 
during MET) and others typically down regulated during EMT (i.e. up regulated during 
MET) (Table B.5) [97-100]. In an effort to identify those EMT/MET-associated genes that 
may be contributing to the differential response of the cell-lines to miRNA over expression, 
we sought to identify genes targeted by the over-expressed miRNAs that display changes 
in levels of expression consistent with the miRNA-induced changes in morphology and 
correlated EMT scores (Table B.6-8). For example, repressor gene ZEB1 previously has 
been shown to be expressed at relatively lower levels in epithelial-like cells and relatively 
higher levels in mesenchymal-like cells [75, 101]. Since ZEB1 is a direct target of miR-
429, the expression of ZEB1 is expected to be down regulated in each of the three 
mesenchymal-like cell lines displaying morphological changes characteristic of MET. 
Consistent with this prediction, ZEB1, as well as its paralog ZEB2, and three other direct 
targets of miR-429 (FN1, MSN, ITGAV) previously associated with high expression in 
mesenchymal-like cells were significantly down regulated in all three cell lines in response 
to miR-429 over expression (Table B.8). In addition, four other EMT/MET genes 
previously associated with high expression in mesenchymal-like cells, but not direct targets 
of miR-429, were also significantly down regulated, again underscoring the apparent 
importance of indirect miRNA-induced regulatory changes in EMT/MET.   
 51 
  In contrast to miR-429, over expression of miR-205 was observed to induce MET 
in HEY and SK-OV-3 cells but not in PC-3 cells. Consistent with the miR-205-induced 
changes in morphology/EMT scores, EMT/MET genes previously associated with high 
expression in mesenchymal-like cells were significantly down regulated in HEY and SK-
OV-3 cells, but displayed either no significant change in expression (ZEB 2, PTP4A1) or 
were significantly up regulated (TCF4, GNG11) in PC-3 cells (Table B.7).  
 Over expression of miR-203a induced changes in morphology and in EMT scores 
in PC-3 cells but not in HEY or SK-OV-3 cells. Consistent with these observations, 
nineteen EMT/MET genes displayed correlated changes in expression characteristic of 
MET in PC-3 cells but no correlated change in expression in HEY or SK-OV-3 cells (Table 
B.6). 
 Of the 27 EMT/MET genes displaying changes in patterns of expression correlated 
with the miRNA-induced changes in morphology/EMT scores, only five (ZEB1, ZEB2, 
GNG11, TCF4, KRT19) were responsive to more than one of the over expressed miRNAs. 
This observation coupled with the fact that the majority of the 84 EMT/MET genes did not 
display significant changes in expression correlated with the miRNA-induced changes in 
morphological/EMT scores, is consistent with prior evidence that molecular changes 




3.4.7 Variability in the response of HEY, SK-OV-3 and PC-3 cells to miRNA over 
expression likely involves differences in cell-specific trans-regulatory controls 
A major factor in the regulation of genes by miRNAs is the degree of complementarity 
between the miRNA sequence (especially the 7-8 nucleotide "seed region") and one or 
more "target sequences" typically located within the 3' untranslated region (UTR) of 
regulated genes. For example, we have previously shown that even a single nucleotide 
change within the seed region of the miR-200 family of miRNAs is sufficient to 
significantly disrupt regulatory control of target genes expression [9]. Thus, one possible 
explanation of the differential regulatory response of genes to over expression of the same 
miRNA in different cells types is sequence variation between cells in the miRNA target 
sequences of regulated genes. To explore the possibility that such sequence variation may 
be contributing to the differential response of target genes to miRNA over expression in 
SK-OV-3 and PC-3 cells, we downloaded processed whole exome sequencing files of  
NCI-60 cell lines from CellMiner database [103] (Note that HEY cells are not one of the 
NCI-60 cell lines and thus sequence data are unavailable).  
 Sequence comparison of the 3’ untranslated regions (UTRs) of target genes 
differentially responding to over expression of the same miRNA in PC-3 and SK-OV-3 
cells (from genes listed in Table B.6-8) failed to uncover any sequence variation between 
the cell lines in miRNA target regions (Table B.9). Thus, in so far as sequence variation 
within the 3’ UTRs between SK-OV-3 and PC-3 cells is representative, it appears that 
variation in the miRNA target sequences of regulated genes is unlikely to be a primary 
cause of the differential regulatory response of genes to over expression of the same 
miRNA in different cell lines.  
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 An alternative explanation of the differential response of target genes to over 
expression of the same miRNAs in different cells is cell-specific variation in trans-
regulatory controls capable of directly or indirectly modulating the action of miRNAs. For 
example, ectopic over expression of miR-203a results in down regulation of its target gene 
SNAIL2 in HEY and SK-OV-3 cells but not in PC-3 cells (Table B.10). Two known 
repressors of SNAIL2 (CREB1 and SUZ12) are down regulated in PC-3 cells but not in 
HEY and SK-OV-3 cells possibly negating/overriding the down-regulatory effect of miR-
203a over expression on SNAIL2 in PC-3 cells. Other scenarios are possible and will 
become better defined as our understanding of the complexities of variation in gene-gene 
regulatory interactions between cells becomes better understood.  
 
3.5 Discussion 
MiRNAs are widely recognized as a major component of post-transcriptional regulatory 
control in eukaryotes [104]. Modulations in the expression of miRNAs have been 
associated with a variety of diseases [105] including cancer where they are being developed 
as biomarkers of early disease onset [106] , as well as, a potential new class of therapeutic 
agents [107]. The observation that there can be considerable variation in the functional 
consequence of ectopic over expression of the same miRNAs in different cell lines 
emphasizes the importance of host cell-miRNA interactions, as well as, the importance of 
understanding of the molecular basis of this phenomenon as a pre-requisite to clinical 
application.   
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 In an effort to better understand and characterize the molecular basis of host cell-
miRNA interactions, we systematically studied the morphological and molecular 
consequences of ectopic over expression of three sequentially divergent miRNAs 
previously implicated in the EMT/MET process in three distinct mesenchymal-like cancer 
cell lines. Two of these cell lines were derived from ovarian cancers (HEY and SK-OV-3) 
and the other was derived from a prostate cancer (PC-3).  Whole transcriptome microarray 
profiling established that an average of 6624 genes were significantly differentially 
expressed in each of the cell lines in response to ectopic over expression of each of the 
three miRNAs. Consistent with earlier results, only a minority of these differentially 
expressed genes was found to be direct targets of the miRNAs. This finding demonstrates 
that changes in miRNA expression levels trigger a cascade of cellular responses extending 
well beyond those induced in directly targeted genes. Indeed, on average 21.3% of the 
significantly differentiated genes are predicted to be directly targeted by one or other of the 
three miRNAs.  
 Consistent with earlier studies demonstrating that the transition from an epithelial 
to mesenchymal cell type (EMT) is a graded, step-wise process [102], we found significant 
differences between the three cells lines in morphological and molecular indices of  cell 
type. Although all three cell lines have previously been described as mesenchymal-like, 
HEY cells were found to display the most elongated morphology and pronounced 
mesenchymal molecular index. PC-3 cells were found to be intermediate both 
morphologically and on the molecular level, while SK-OV-3 cells displayed the most 
epithelial-like morphologies and molecular profiles.  
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 Ectopic over expression of the three miRNAs in each of the cell lines resulted in 
remarkedly different results. Over expression of miR-429 induced significant 
morphological and molecular changes characteristic of MET in all three cell lines. In 
contrast, over expression of miR-205 resulted in significant changes in these parameters in 
HEY and SK-OV-3 cells but not in PC-3 cells, while over expression of miR-203a resulted 
in morphological and molecular changes characteristic of MET only in PC-3 cells. These 
results suggest that differential responses to future miRNA-based therapies should be 
anticipated not only between different types of cancer but perhaps in different patients with 
the same cancer as well.  
 In an effort to explore the possible molecular basis of the varied responses of 
different cells to the same miRNA treatment, we focused on a set of genes previously 
identified as being directly or indirectly involved in EMT/MET in one or another cellular 
context. As was the case for all differentially expressed genes, only a minority of the 
EMT/MET genes was predicted to be direct targets of the miRNAs, again underscoring the 
importance of indirect changes induced in response to modulations in miRNA expression. 
In contrast to what was found for all differentially expressed direct and indirectly targeted 
genes, the majority of differentially expressed EMT/MET-associated genes were expressed 
in common in each miRNA-cell type combination. This is likely a reflection of selective 
enrichment in the targeting of EMT/MET genes by these MET-inducing miRNAs.   
 
 To identify EMT/MET genes that may be directly contributing to the differential 
response of the cell-lines to miRNA over expression, we identified 27 genes directly 
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targeted by the over expressed miRNAs that displayed changes in levels of expression 
consistent with the miRNA-induced changes in morphology and correlated EMT scores. 
Only five of these 27 genes were similarly responsive to the over expression of each of the 
three miRNAs consistent with earlier evidence that the drivers of EMT/MET can vary 
significantly between cells. Also consistent with this view is the fact that the majority of 
the 84 EMT/MET genes did not display changes in expression correlated with the miRNA-
induced changes in morphological/EMT scores in any of the three cell lines examined. 
Based on comparative sequence analysis of the target sequences of miRNA regulated genes 
in SK-OV-3 and PC-3 cells, we conclude that the molecular basis of the variable response 
of different cell lines to miRNA over expression is likely not primarily attributable to 
variation in cis-regulatory sequences in the UTR of targeted genes but rather to cell-specific 
variation in genes that can modulate the action of miRNAs. 
 Collectively our results indicate that miRNA-mediated regulation of EMT/MET, 
like other pathways implicated in cancer onset and progression [108], is a highly integrated 
process that can be significantly modulated by the molecular background of different cells. 
The overall clinical implication of our study is that the future utility of any given miRNA 
in cancer diagnostics and therapeutics is likely to be cancer-type and possibly individual 




CHAPTER 4. EVIDENCE FOR THE IMPORTANCE OF POST-
TRANSCRIPTIONAL REGULATORY CHANGES IN OVARIAN 
CANCER PROGRESSION AND THE CONTRIBUTION OF MIRNAS 
4.1 Abstract 
Objective: To explore the relationship between RNA and protein expression in the 
context of ovarian cancer metastasis by systematically comparing of the expression of 4436 
genes on the RNA and protein levels between primary and metastatic samples collected 
from the same ovarian cancer patient. 
Methods: Cancer cells were isolated from bulk primary and metastatic (omentum) 
tissues by laser capture microdissection. mRNA expression was measured by microarray 
and protein expression a highly sensitive mass spectrophotometric method.  
Results: The overall correlation between changes in levels of mRNA and their 
encoding proteins is low (r=0.38). The majority of changes in levels of expression are on 
the protein level with no corresponding change on the mRNA. Computational and 
experimental evidence demonstrates that a significant fraction of the discordant changes in 
levels of RNA and protein between primary and metastatic cancer samples is mediated by 
microRNAs. The majority (>60%) of changes in RNA and protein levels between the 
primary and metastatic samples of the same ovarian cancer patient are not correlated 
underscoring the limitations of functional pathway predictions based on RNA profiling 
alone. Indirect and direct evidence indicates that much of the observed discordance may 
be attributed to changes in miRNA expression.  
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Conclusions: Our findings are consistent with growing evidence of the importance 
of post-transcriptional/translational changes in the onset and progression of ovarian and 
other cancers and the significance of miRNAs in regulating the process. 
 
4.2 Introduction 
The last several decades have witnessed historic breakthroughs in the development of new 
high-throughput technologies to detect molecular changes associated with cancer onset and 
progression. The detection of these molecular changes, combined with appropriate 
computational methods, has proven extremely useful in the establishment of highly 
accurate diagnostic markers of the disease [74, 75]. The functional significance of the 
detected changes has proven more difficult to interpret because of our limited 
understanding of the underlying causal mechanisms involved [76]. A case in point is the 
relationship between changes in levels of RNA transcripts and corresponding changes (or 
lack thereof) in levels of their encoded proteins [77]. For example, high-throughput 
technologies have identified significant changes in patterns of mRNA expression between 
cancer patient primary and metastatic samples but the functional significance of these 
changes often rests upon the assumption that observed changes in levels of mRNA 
accurately reflect changes in levels of their encoded proteins [78, 79]. The validity of this 
assumption is far from confirmed and is, in fact, questionable in light of increasing 
evidence of the importance of post-transcriptional mechanisms in both the onset and 
progression of many cancers [80, 81].   
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We report here the results of a systematic comparison of the expression of 4436 
genes on the RNA and protein levels between tumor samples collected from the ovary (OV) 
and omentum (OM) of same ovarian cancer (OC) patient. Consistent with other recent 
studies [82-84], our results indicate that the overall correlation between differences in 
levels of mRNA and their encoding proteins is low (r=0.38). We find that the majority of 
the differences in levels of expression are on the protein level with no corresponding 
change on the mRNA level implying the importance of post-transcriptional regulatory 
mechanisms. The results of gene ontology (GO) analyses further support this conclusion.  
Finally, we present evidence that a significant fraction of the discordant differences in 
levels of RNA and protein between the OV and OM cancer samples is mediated by 
microRNAs.  
 
4.3 Materials and Methods 
4.3.1 Tissue collection 
Cancer tissues from the right ovary and omental sites were collected from a woman with 
stage IIIc, grade 2/3 serous adenocarcinoma at Northside Hospital (Atlanta, GA) after 
informed consent was obtained under appropriate Georgia Institute of Technology 
Institutional Review Board protocols (H14337) according to previously described methods 
performed in accordance with the relevant guidelines and regulations [79].  Briefly, 
following resection, the tumor tissues were placed in cryotubes and immediately (<1 
minute) frozen in liquid nitrogen. Samples were transported on dry ice to Georgia Institute 
of Technology (Atlanta, GA), and stored at -80 ºC. After examination and verification by 
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a pathologist, tissues were embedded in cryomatrix (Shandon, ThermoFisher, Waltham, 
MA). For each tissue sample, 8μm frozen sections were cut and attached to uncharged 
microscope slides. Following dehydration and staining (HistoGene, LCM Frozen Section 
Staining Kit, Arcturus, ThermoFisher), slides were processed in an Autopix (Arcturus) 
instrument for laser capture microdissection (LCM). CapSure Macro-LCM Caps 
(Arcturus) were used to ensure purity of all collected cells. Approximately 30,000 cells 
were collected for each of the tissue samples. 
 
4.3.2 RNA extraction and amplification 
RNA extraction and amplification  were performed according to previously described 
methods [79]. miRNAs were isolated from the cells using the miRNeasy Micro KIT 
(Qiagen, Germantown, MD). The quality and quantity of miRNAs were assessed on the 
Bioanalyzer RNA Pico Chip (Agilent Technologies, Santa Clara, CA). Labeling of 
miRNAs was performed with the FlashTag Biotin HSR RNA Labeling Kit (Affymetrix) 
and hybridized to GeneChip® miRNA 3.0 Array chips (Affymetrix, ThermoFisher). 
 
4.3.3 Microarray analysis 
Each individual RNA sample was analyzed both for miRNA and mRNA. miRNA profiling 
analysis was conducted on the GeneChip® miRNA 3.0 Array (Affymetrix). mRNA 
transcriptome analysis was analyzed using Gene Chip Human Transcriptome Array U133 
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2.0 (Affymetrix). In total, six miRNA and mRNA (two individual samples in triplicate) 
global expression data sets were generated in this study.  
 Raw miRNA and mRNA expression data were processed using Affymetrix 
Expression Console (EC) Software Version 1.4. Briefly, raw data probes were normalized 
using SST-RMA algorithm. The normalized expression values were log2 transformed. 
Differentially expressed mRNAs or miRNAs were identified through fold change and p-
value calculated using two-tail Student t-test. 
 
4.3.4 Tissue homogenization, protein extraction and digestion 
The minced tissue samples are dounced with tight dounce homogenizer in ice-cold 
homogenization buffer containing 0.25 M sucrose, 1 mM EDTA, 10 mM HEPES-NaOH, 
protease inhibitor mixture (Roche Diagnostics, Indianapolis, IN), pH 7.4 with 40 strokes 
on ice. The solutions were centrifuged at 1,000 g for 10 minutes at 4 ºC. The supernatant 
was kept, and the tissue pellets were re-suspended in RIPA buffer containing 100 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH=7.9, 150 mM NaCl, 0.5 
% sodium dodecyl sulfate (SDS), benzonase (1 U/mL), and protease inhibitor mixture 
(Roche Diagnostics). After complete solubilization of nuclei and digestion of genomic 
DNA, the lysate was centrifuged at 25,000 g for 10 minutes at 4 ºC. The supernatants were 
combined, and proteins were reduced by 5 mM DTT (56 °C, 25 min) and alkylated with 
15 mM iodoacetamide (RT, 30 minutes in the dark). Proteins were purified with the 
chloroform-methanol precipitation method. Purified proteins were digested with Lys-C 
(the ratio of Lys-C and protein was about 1:50) at 31ºC for 15 hours followed by trypsin 
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digestion at 37 ºC for 4 hours. Digestion was quenched by the addition of 10% TFA to a 
final concentration of 0.4%, and the resulting peptides were purified using a Sep-Pak tC18 
cartridge (Waters, Milford, MA). 
 
4.3.5 Peptide TMT labelling, fractionation and LC-MS/MS analysis 
Purified and dried peptides from each sample were tagged with TMT reagents. Each 
sample was labeled using two channels (i.e. the peptides from the tumor tissue of the right 
ovary were labeled with channel 126 and 127 and the peptides of tumor tissue taken from 
the omentum were with 128 and 129). The four labeled peptide samples were combined 
and desalted using a tC18 Sep-Pak cartridge. Then peptides were fractionated using high-
pH reversed phase high performance liquid chromatography (HPLC) (pH=10). The sample 
was fractionated into 20 fractions.  Each fraction was purified, dried and dissolved in a 
solvent containing 5% ACN and 4% formic acid (FA), and 4 μL was loaded onto a 
microcapillary column packed with C18 beads (Magic C18AQ, 5 μm, 200 Å, 100 μm x 16 
cm) using a WPS-3000TPLRS autosampler (Dionex, Sunnyvale, CA). Peptides were 
separated by reversed-phase chromatography and detected in a hybrid dual-cell quadrupole 
linear ion trap – Orbitrap mass spectrometer (LTQ Orbitrap Elite, ThermoFisher) using a 
data-dependent Top 15 method. For each cycle, one full MS scan (resolution: 60,000) in 
the Orbitrap at 106 AGC target was followed by up to 15 MS/MS for the most intense ions. 
Selected ions were excluded from further analysis for 90 s each. Ions with at least double 
charges were sequenced. MS/MS scans were activated by HCD at 40.0% normalized 
collision energy with 1.2 m/z isolation width and detected in the orbitrap cell. 
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4.3.6 Database searching, data filtering, and quantification 
The raw files recorded by MS were converted into mzXML format. Precursors for MS/MS 
fragmentation were checked for incorrect monoisotopic peak assignments [85]. All 
MS/MS spectra were matched against a database encompassing sequences of all proteins 
in the Uniprot Human (Homo sapiens) database and common contaminants such as keratins 
using the SEQUEST algorithm (version 28) [86]. Each protein sequence was listed in both 
forward and reversed orientations to control and estimate the false discovery rate (FDR) of 
peptide identifications. The following parameters were used for the database search: 10 
ppm precursor mass tolerance; 0.1 Da product ion mass tolerance; full trypsin digestion; 
up to two missed cleavages; variable modifications: oxidation of methionine (+15.9949); 
fixed modifications: carbamidomethylation of cysteine (+57.0214), N-terminus and lysine 
TMT modification (+229.1629).   
 The target-decoy method was employed to evaluate and further control FDRs of 
peptide identification [87, 88], and linear discriminant analysis (LDA) was utilized to 
distinguish correct and incorrect peptide identifications based on multiple parameters such 
as XCorr, ΔCn, and precursor mass error [85, 89-91]. After scoring, peptides less than six 
amino acid residues were deleted and peptide spectral matches were filtered to a less than 
1% FDR based on the number of decoy sequences in the final data set, then the data set 
was further filtered to <1% FDR at the protein level. 
 Quantification of confidently identified peptides was based on the TMT reporter 
ion intensities in MS [92]. The isotopic information provided by the company 
(ThermoFisher) was used to calibrate the measured intensities. The median intensity ratio 
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for each unique peptide in each channel was obtained, and eventually the protein ratio is 
the median value of all unique peptides for the corresponding protein. 
 
4.3.7 Integration of transcriptomic and proteomic profiles 
4436 genes detected by mass spectrometry (FDR<0.01) were mapped to at least one probe 
set on the HTA 2.0 array by coding gene name matching. For genes with multiple mRNA 
probes corresponding to a single protein, the probe with the highest average expression 
level among OV and OM samples was used in the integrated dataset [93].  
 
4.3.8 miRNA target prediction 
The miRNA target prediction (based on mirSVR) was downloaded from microRNA.org 
(August 2010 release) [59]. The mirSVR score refers to targets of microRNAs with scores 
obtained from their support vector regression algorithm [94]. To reduce the occurrence of 
false positives, only predicted targets with a mirSVR score less than -0.1 were considered. 
 
4.3.9 Pathway enrichment analysis 
Differentially expressed genes on mRNA and protein levels were employed for enrichment 
analysis using the MetaCore suite 6.29 build 68,613 (Thomson Reuters, New York, NY). 
Briefly, significantly perturbed pathways and process networks were identified by mapping 
differentially expressed genes onto manually curated GeneGO canonical pathway maps 
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and cell process network models [95]. The statistical significance of enrichment was 
evaluated using p-values calculated based on hypergeometric distribution. Pathways were 
considered to be significantly enriched if their p-values were < 0.05.  
 
4.3.10 Cell culture and microRNA transfection 
The HEY cell line was kindly provided by Gordon Mills, Department of Molecular 
Therapeutics, University of Texas, MD Anderson Cancer Center. Cells were cultured in 
RPMI 1640 (Mediatech, Manassas, VA) supplemented with 10% FBS (Fetal Bovine 
Serum; Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-antimycotic solution 
(Mediatech). For miRNA transfections, 6 × 104 cells were seeded per well in 24-well 
plates. Cells at exponential phase of growth were transfected with 30 nM miRNA 
purchased as Pre-miR miRNA Precursors (Ambion, Austin, TX) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) and per the manufacturer’s instructions. Cells were allowed to 
grow for 48 hours before RNA isolation. Ambion Pre-miR miRNA Precursor Negative 
Control was used as a negative control. 
 
4.3.11 Real-time PCR 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). Four micrograms 
of RNA was reversed transcribed into cDNA using the Superscript III First-Strand 
Synthesis System (Life Technologies, ThermoFisher) according to the manufacturer's 
instructions. Real-time PCR was performed using TaqMan® Real-Time PCR Master 
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Mixes (Applied Biosystems, ThermoFisher) on a CFX96 Real-Time System (Bio-Rad, 
Hercules, CA). Expression values were normalized using GAPDH as a reference gene. 
Normalization and fold-change were calculated using the ∆∆Ct method.  
 
4.3.12 Western Blot 
The total protein concentration of the supernatant was determined using a protein assay 
reagent kit (Bio-Rad). To the lysates, equal volumes of 2X Laemmli sample buffer were 
added and the samples were heated to 90 °C for 5 minutes. Equal amounts of proteins were 
separated by 4–20% gradient precast TGX gel (Bio-Rad) and transferred to nitrocellulose 
membrane (Bio-Rad). Membranes were blocked with 5% nonfat dry milk in 10 mM Tris 
buffered saline. After blocking, the membranes were probed with the primary antibody for 
overnight at 4°C with gentle rocking. Antibodies used are against cathepsin B (CTSB 
antibody Cat # 365558, 1:100 dilutions; Santa Cruz Biotechnologies, Dallas, TX), I-Plastin 
(PLS1 antibody Cat # 386830, 1:200 dilutions; Santa Cruz Biotechnologies), and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH antibody Cat # 47724, 1:100 
dilutions; Santa Cruz Biotechnologies). Appropriate secondary antibodies were used at 
1:5,000 dilutions (Santa Cruz Biotechnologies). After incubation with specific horseradish 
peroxidase–conjugated secondary antibody (goat anti-mouse horseradish peroxidase–
(HRP) conjugated secondary antibody (sc-2005, Santa Cruz Biotechnologies), donkey 
anti-goat horseradish peroxidase–(HRP) conjugated secondary antibody (sc-2020, Santa 
Cruz Biotechnologies), protein was visualized using the enhanced chemiluminescence 
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detection system (Pierce, ThermoFisher). The quantification of western blot bands was 
performed using ImageQuant software (GE Healthcare, Chicago, IL). 
 
4.3.13 Data availability 
The microarray datasets supporting the conclusions of this article are available in the Gene 




4.4.1 The majority of changes in gene expression between tumor samples collected from 
the ovary and omentum of the same patient occur at the post-transcriptional level.  
To systematically explore the relationship between RNA and protein expression, we 
integrated quantitative transcriptional and proteomic profiles of cancer cells isolated by 
laser capture microdissection from bulk tumor samples collected from the ovary (OV) and 
the omentum (OM) of the same patient. Expression of mRNA was measured by microarray 
(Affymetrix Human Transcriptome Array 2.0) as previously described [79]. Protein 
expression was measured using a recently developed, highly sensitive mass 
spectrophotometric method [96].  
Of the 18,643 genes displaying detectable levels of RNA (Table C.1), the 
expression of only 4436 were detectable on the protein level (FDR<0.01; Table C.2).  The 
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overall correlation between changes in levels of mRNA and protein encoded by these 4436 
genes between the OV and OM samples was low (r=0.38) (Figure 4.1 A), in part, because 
the majority of the genes displayed little or no change in expression between the OV and 
OM samples. Of the 4436 genes detected in both our mRNA and protein expression 
datasets (Figure 4.2; Table C.3), the majority (2490 genes) displayed no significant change 
in expression (< 1.5-fold change) on either the mRNA or protein levels.  Of the 1946 genes 
displaying a significant change (> 1.5-fold) in expression between the OV and OM 
samples, 230 were significantly differentially expressed on both the mRNA and protein 
levels, 1467 were significantly differentially expressed on the protein level but not on the 
RNA level and 249 on the RNA level but not on the protein level. The overall correlation 
between changes in RNA and protein for the 1946 significantly differentially expressed 
genes (Figure 4.1 B; r =0.41, p=3.376×10-79) is in general agreement with similar 
comparative studies previously carried out on a variety of mammalian tissues, tumors 
and/or cell lines [82-84, 97-99]. This overall correlation is not greatly affected by 
increasing the stringency of the cut-off value used in the analysis (Table 4.1).  
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Figure 4.1. Correlation between changes in RNA and protein. Scatterplots with 
associated correlation coefficients(r) for (A) genes detected in both our mRNA and 
protein expression datasets (n=4436); (B) genes displaying a significant (p=3.376×10-
79) change in expression between the OV and OM samples (n=1946). 
 
Table 4.1. Effects of fold change cut off on Pearson correlation coefficient of 
differentially expressed genes on mRNA and protein levels. 
Fold 
change r p-value 
1.2 0.39 2.5E-121 
1.5 0.41 3.38E-79 
1.8 0.40 8.62E-49 
2 0.40 2.38E-35 
2.2 0.38 5.29E-26 





Figure 4.2. Diagram representing the classification of the integrated transcriptomic 
and proteomic datasets. Step 1: Integration of transcriptomic and proteomic profiling 
based on gene symbol matching. Step 2: Classification of differentially expressed 
genes into groups based upon changes in their respective mRNA and protein levels in 
OV and OM samples. 
 
We further classified genes differentially expressed between the OV and OM 
samples into three groups based upon changes in their respective mRNA and protein levels:  
The positively correlated (PC) group is comprised of genes displaying positively correlated 
changes in mRNA and protein levels between the OV and OM samples [i.e., up (mRNA)-
up (protein) (U-U); down-down (D-D)]; the negatively correlated (NC) group is comprised 
of genes displaying negatively correlated changes in mRNA and protein levels between the 
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OV and OM samples [i.e., up (mRNA)-down (protein) (U-D); down-up (D-U)]; and the 
uncorrelated (UC) group is comprised of genes displaying significant changes in the 
expression of either protein or mRNA levels but not both [i.e., up (mRNA)-no change 
(protein) (U-NC); no change-up (NC-U); down-no change (D-NC); no change-down (NC-
D)]. As shown in Figure 4.3 A, the combined percentage of genes displaying uncorrelated 
changes (NC-D, NC-U, D-NC, and U-NC) in mRNA and protein levels between the OV 
and OM samples (88%) far exceeds the percentage of genes (12%) displaying correlated 
changes. This suggests that the vast majority of changes in gene expression between the 
OV and OM samples involve processes occurring on the post-transcriptional/translational 
level. As shown in Figure 4.3 B, most of the uncorrelated changes are in the NC-U sub-
group (43%) followed by the NC-D sub-group (32%), the U-NC (7%) and D-NC (6%) sub-
groups. Most of the positively correlated changes are in the U-U subgroup (135/199 = 68%) 
with only 32% (64/199) of the positively correlated changes being in the D-D subgroup. 
The relatively few changes (1.3%) comprising the negatively correlated group are 
contained predominantly in the D-U subgroup (25 genes) with only six genes being in the 
U-D subgroup.  
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Figure 4.3. Pie chart showing the distribution of genes in correlated and uncorrelated 
groups. (A) The combined percentage of genes displaying correlated changes (U-U, 
D-D, D-U, and U-D) and uncorrelated changes (NC-D, NC-U, D-NC, and U-NC) in 
mRNA and protein levels between the OV and OM. (B) The percentage of genes in 
each subgroup of correlated and uncorrelated changes. 
 
4.4.2 Gene ontology analyses implicates EMT in the differences observed between 
samples and underscores the limitations of predictions drawn from RNA profiling 
alone.  
In an effort to evaluate the potential functional significance of the observed changes in 
RNA and protein expression between the OV and OM samples, we employed gene 
ontology analyses to compare biological pathways enriched for genes identified as 
significantly differentially expressed on the RNA and protein levels. Using the combined 
RNA and protein datasets (1946 genes), a total of 250 biological pathways were identified 
as being significantly (p < 0.05) enriched among genes differentially expressed between 
the OV and OM samples. Using the RNA expression dataset alone, 73 pathways were 
identified as being significantly enriched, while 218 were significantly enriched using the 
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protein dataset alone (Table C.4, Table C.5). There was an overlap of only 41 biological 
pathways (16%) enriched in the two datasets (Figure 4.4 A, 4.4 B). More than half of the 
41 overlapping biological pathways uncovered in our analysis (e.g., cell adhesion and 
cytoskeleton remodeling, etc.) are either directly or indirectly associated with epithelial-
to-mesenchymal transition (EMT)- a cellular function believed to be critical in cancer 
metastasis [100, 101]. 
While the 41 overlapping pathways constitute the majority of those predicted from 
the RNA dataset alone (41/73 = 56%), nearly half of the pathways predicted to be 
significantly overrepresented from the RNA dataset are likely spurious since these RNA 
changes are not manifest on the protein level. This finding coupled with the fact that >80% 
(177/218) of the pathways predicted from the protein dataset were not predicted from the 
RNA dataset points to the limitations of functional pathway predictions drawn from RNA 
profiling alone. 
 The fact that many pathways known to be central to EMT and other aspects of 
metastasis were significantly enriched among genes differentially expressed on the protein 
but not the RNA level (e.g., development-TGF-beta-dependent induction of EMT via 
MAPK, cell adhesion-role of tetraspanins in the integrin-mediated cell adhesion, 
cytoskeleton remodeling-Fibronectin-binding integrins in cell motility, etc.) further 
supports the functional importance of post-transcriptional/translational regulatory controls 




Figure 4.4. Results of GeneGo pathway enrichment analysis. (A) 41 GeneGo pathways 
significantly enriched in differentially expressed genes on either mRNA or protein 
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level. (p-value < 0.05) (B) Venn diagram shows the number of enriched GeneGo 
pathways of each dataset that were found to be significantly enriched. (p-value < 0.05) 
 
4.4.3 Differences in microRNA (miRNA) expression contribute to post-
transcriptional/translational changes between the OV and OM samples.  
The discordance between changes in levels of protein and their encoding mRNAs can be 
explained in a variety of ways including differences in relative rates of in vivo synthesis 
and stability [102]. While some differences in RNA/protein stability can be attributed to 
inherent differences in molecular structure, emerging evidence suggests that relative rates 
of both protein synthesis and RNA/protein stability are often post-transcriptionally 
regulated by microRNAs (miRNAs) [103]. 
 MiRNAs are small, non-encoding regulatory RNAs that can post-transcriptionally 
regulate levels of RNA and protein by degrading targeted mRNAs and/or by repressing 
translation of targeted mRNA transcripts [104]. To explore the possible role of miRNAs in 
the observed discordance between mRNA and protein levels between the OV and OM 
samples, we measured changes in levels of miRNAs and correlated these changes with 
corresponding changes in levels of mRNA and protein of their targeted genes. Differences 
in levels of miRNAs between the OV and OM samples were determined by microarray 
(Affymetrix GeneChip® miRNA 3.0 Array) and the mRNAs targeted by the differentially 
expressed miRNAs predicted using the miRanda-mirSVR algorithm [94]. Our focus was 
on genes displaying significant decreases in protein levels in the OM sample with no 
corresponding change in levels of mRNA (NC-D group). Our goal was to test the 
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hypothesis that at least some of the observed discordance might be explained by the up-
regulation of regulatory miRNAs.  
 The NC-D group is comprised of 622 genes, 592 of which are predicted to be 
targeted by 1100 miRNAs (Table C.6). Of these 1100 miRNAs, 101 are significantly 
differentially expressed between the OV and OM samples (Table C.7) and 48 of these are 
significantly up regulated in the OM sample (Table C.8). For example, the 10 most 
significantly up-regulated of these miRNAs and the number of their predicted gene targets 
in the NC-D and D-D groups is shown in Table 1. Interestingly, the gene targets of miRNAs 
significantly up regulated in the OM sample are contained in both the D-D and NC-D 
groups (Table C.9, Table C.10).  This implies that individual miRNAs up regulated in the 
OM sample may be regulating some genes on the transcriptional level (effecting down 
regulation of mRNAs and correlated changes on the protein level) and some genes on the 
translational level (effecting levels of protein with no correlated change on the mRNA 
level).  
 In an effort to independently validate the observation that single miRNAs may 
preferentially regulate different genes on different levels (i.e., transciptionally vs. post-
transcriptionally), we selected the most significantly up-regulated miRNA in OM, hsa-
miR-363-3p, and exogenously over-expressed it in the well-characterized HEY ovarian 
cancer cell line [105]. Forty-eight hours after transfection of miR-363-3p in HEY cells, we 
extracted mRNA and protein, and monitored levels of two randomly selected genes, one 
from the D-D group (CTSB, Cathepsin B) and one from the NC-D group (PLS1, Plastin1). 
Western blots demonstrate that levels of CTSB and PLS1 protein are both decreased in 
cells in which hsa-miR-363-3p was over expressed (Figure 4.5 A, 4.5 C). RT-PCR 
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quantification of mRNA levels of these two genes showed a significant decrease in CTSB 
mRNA levels but no significant change in levels of PLS1 mRNA (Figure 4.5 B). The 
results of this experiment are consistent with the results of our RNA microarray and protein 
mass spectrometric analyses indicating that changes in levels of the same miRNAs may 
alternatively regulate levels of RNA and/or proteins in a gene-specific manner.  
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Figure 4.5. Effects of over-expression of miR-363-3p in HEY cells on the mRNA and 
protein expression of its predicted targets CTSB and PLS1. (A) Relative protein 
expression levels of CTSB and PLS1 as determined by Western blot. (B) Relative 
mRNA expression of CTSB and PLS1 as determined by qRT-PCR shows a significant 
decrease in CTSB mRNA levels but no significant changes on levels of PLS1. 
Expression values are normalized to negative control group and represent mean ± SD 
of at least three biological replicates each performed in three technical replicates. 
Asterisks represent statistically significant differences from the negative control 
group. (**: p<0.05) (C) Western blot analysis of CTSB and PLS1 proteins both 




Modern DNA sequencing methods can identify genetic differences in cancer vs. normal 
tissues with nucleotide precision.  Similarly, microarray, RNA sequencing and related 
high-throughput methodologies can quantitate changes in levels of gene expression on the 
RNA level with remarkable accuracy. The problem is that although the consequences of 
nearly all genome-wide molecular level changes manifest their functional significance on 
the protein level, global changes in the levels of protein are not easily and economically 
monitored by current methods. As a consequence, global changes in protein levels 
associated with cancer onset and progression are typically not directly measured but rather 
inferred from more easily monitored changes on the RNA level. The validity of these 
inferences is often questionable and, in some instance, may be misleading [81, 106]. For 
example, modern cancer medicine is rapidly embracing the molecular profiling of patient 
tumors in order to personalize targeted gene therapies [107]. Significant over-expression 
of a particular "cancer driver" gene on the RNA level may suggest treatment with a 
chemical inhibitor of the protein encoded by the over-expressed RNA. This may be a 
reasonable therapeutic strategy but only if elevated levels of mRNAs are an accurate 
reflection of levels of the targeted proteins.   
 The purpose of this study was to explore the system-wide relationship between 
differences in gene expression on the RNA and protein levels between tumor samples 
collected from the same patient. Using recently developed proteomic methodologies, we 
were able to explore this question on a global, level by directly comparing the expression 
of 4436 genes simultaneously on the RNA and protein levels. 
 80 
 We compared system-wide changes in levels of RNA and protein between discrete 
tumor samples collected from the ovary and the omentum of the same OC patient. 
Comparing molecular profiles between samples collected from the same patient removes 
the ambiguities associated with between-patient variation and allowed us to focus on 
changes associated with tumor progression within a single patient.  Our results indicate that 
the majority of changes in mRNA and protein expression are not correlated with one 
another, consistent with emerging evidence for the importance of post-
transcriptional/translational regulation in various aspects of cancer onset and progression 
[106].  
 There remains controversy as to whether OC metastases originate from primary 
tumors in the fallopian tube, in the ovary or both24. While our studies do not resolve this 
controversy, our gene ontology (GO) analyses indicate that, for the patient analyzed in this 
study, the majority of biological pathways associated with the RNA and protein level 
changes between the OV and OM samples are associated with EMT. This is consistent with 
the growing body of evidence that EMT is critical to the metastatic process [100, 101]. The 
fact that the majority of changes in biological pathways between the OV and OM samples 
were predicted from the observed changes in protein and not RNA levels further supports 
the importance of post-transcriptional regulation in metastasis.  
 Because of the growing body of evidence implicating miRNAs in various aspects 
of cancer onset and progression [108], we explored the possibility that miRNAs may be 
contributing to the observed discordance between changes in RNA and protein levels in 
our OV and OM samples. We measured changes in levels of miRNAs between OV and 
OM samples and correlated these changes with corresponding changes in levels of mRNA 
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and protein of their targeted genes. Our focus was on testing the hypothesis that at least 
some of the genes displaying significant decreases in protein levels in the OM sample with 
no corresponding change in levels of mRNA (NC-D group) might be explained by the up 
regulation of regulatory miRNAs.  Consistent with this hypothesis, we found that gene 
targets of miRNAs significantly up regulated in the OM sample are down regulated on the 
RNA and or protein levels. In some instances, individual miRNAs up regulated in the OM 
sample are associated with down regulation of their targeted mRNAs with a correlated 
down regulation on the protein level. In other instances, the same miRNAs up regulated in 
the OM sample were associated with significant down regulation of their targeted proteins 
but no correlated change in levels of their encoding mRNAs indicating a miRNA-mediated 
regulatory block on the translational level. This suggests that individual miRNAs up 
regulated in the OM sample may be regulating some genes on the RNA level and other 
genes on the protein level.  
 The possibility that a single miRNA may preferentially regulate different genes on 
different levels (i.e., transcriptional vs. translational) was corroborated by in vitro studies.  
Although the extensiveness and mechanisms underlying this phenomenon remains to be 
determined, previous studies have shown that the association of miRNAs with RNA 
binding proteins can significantly affect the levels (post-transcriptional and/or 
translational) on which individual miRNAs regulate their target genes [109]. 
  Collectively, our findings indicate that a significant fraction of the discordance in 
changes in RNA and protein levels between our samples are mediated by miRNAs and that 
miRNAs may contribute to the regulatory coordination of changes on the RNA and protein 
levels to enhance metastasis.  
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 Overall, our findings are consistent with growing evidence of the importance of 
post-transcriptional/translational changes in the onset and progression of ovarian and other 
cancers and the potential significance of miRNAs in regulating the process. 
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CHAPTER 5.  CONCLUSIONS 
MiRNAs are important transcriptional and post-transcriptional regulators of gene 
expression. Based on base paring, miRNAs are able to bind to the 3’-UTR of the target 
genes and typically down-regulate their target gene expression [110]. One miRNA is able 
to regulate the gene expression of multiple target genes, and one target gene can be 
regulated by multiple miRNAs [111]. As a result, miRNAs are able to regulate about 60% 
of  the known human genes and are involved in almost every molecular pathway [112]. 
Recent studies have suggested that dysregulated miRNAs are involved in the hallmarks of 
cancer, including sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, activating invasion and metastasis, and inducing angiogenesis [113]. In this 
thesis, I examine the role of miRNAs in regulating EMT/MET in ovarian cancer. 
In the first study (Chapter 2), we show that sequentially divergent miRNAs 
converge to regulate the EMT/MET process through both direct and indirect regulatory 
changes. We present evidence that helps explain how sequentially divergent miRNAs 
(miR-205 and miR-200 family members) are able to induce MET in ovarian cancer HEY 
cells. We first demonstrated that miR-205 and the miR-200 family of miRNAs both induce 
MET in mesenchymal-like ovarian cancer cells by affecting both direct and indirect 
changes in the expression of genes. We next demonstrate that the majority of changes in 
gene expression commonly induced by ectopic over-expression of the miR-200 family of 
miRNAs and miR-205 are the result of indirect regulatory controls, specifically in the 
changes in expression of EMT/MET-associated genes. While only two direct targets of 
these miRNAs (ZEB1 and WNT5A) are commonly down regulated in response to over 
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expression of miR-205 and/or the miR-200 family of miRNAs, down regulation of these 
genes alone or in combination only partially recapitulated the changes induced by the 
miRNAs. This indicates an auxiliary contribution of other direct and/or indirect regulatory 
changes induced in common or individually by the miRNAs. We go on to provide evidence 
that regulation of EMT/MET associated genes by miR-205 is the result of convergent 
evolution brought about by a translocation event linking miR-205 with members of the 
miR-200 family on human chromosome 1 approximately 80 MYA. 
 In the second study (Chapter 3), we explore the impact of genetic difference 
between different cancer cell lines on the function of miRNAs to regulate the EMT/MET 
process. We demonstrate that the overexpression of miR-205 induces a morphological 
change to a more rounded/cuboidal phenotype consistent with MET in the two OC cells 
(HEY and SKOV3) but not in prostate cancer cells (PC3) relative to negative controls. In 
contrast, miR-203a induces morphological changes characteristic of MET in PC3 cells but 
not in the HEY and SKOV3 cells, while miR-429 induces morphological changes 
characteristics of MET in all three of the cell lines. We report that the ability of these 
sequentially divergent miRNAs to induce MET in these cells is found to be associated with 
inherent differences in the starting molecular profiles of the untreated cancer cells, as well 
as, variability in trans-regulatory controls modulating the expression of genes targeted by 
the individual miRNAs. Our results help support the view that miRNAs have significant 
potential as cancer therapeutic agents. 
 Throughout our first two studies, we focused on the regulatory mechanisms of 
miRNAs mostly from the transcriptional level; however, miRNAs have been shown to 
regulate their target gene expression on both the transcriptional and post-transcriptional 
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levels.  In the final study (Chapter 4), we evaluate the importance of post-
transcriptional/translational changes in the metastasis of a stage III ovarian cancer patient 
and the role played by miRNAs in regulating the process. We present evidence that the 
majority of changes in gene expression between tumor samples collected from the ovary 
and omentum of the same patient occur at the post-transcriptional level. We first proved 
that the overall correlation between global changes in levels of mRNAs and their encoding 
proteins is low (r=0.38). We next verified that the majority of differences are on the protein 
level with no corresponding change on the mRNA level. More importantly, we revealed 
the limitation of drawing conclusions of functional predictions of the differentially 
expressed genes from RNA profiling alone. We further validated that a significant fraction 
of the discordance in changes on the RNA and protein levels between our samples are 
mediated by miRNAs. Our results provide an example of the contribution of miRNAs in 
the regulatory coordination of changes on the RNA and protein levels to enhance 
metastasis. 
 All three studies, while taking different approaches, emphasize the scope and 
complexity of miRNA mediated gene expression regulation.  
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APPENDIX A. SUPPLEMENTARY DATA FOR CHAPTER 2 
Table A.1. Gene expression profiles of HEY cells after transfection of miR-NC, miR-
141, miR-200b, miR-205 for 48 hours. Gene expression profiles are normalized and log2 
transformed using the RMA method. 
Table A.2. miRanda predicted target genes of miR-141, miR-200b and miR-205. 3943, 
4027, and 2941 genes are predicted to be direct target genes of miR-141, miR-200b, and 
miR-205, respectively. Among these, 1440 genes are predicted to be direct target genes of 
both miR-141 and miR-200b, but only 444 out of these 1440 genes (30.8%) are predicted 
to be direct target genes of miR-205. 
Table A.3. TargetScan predicted target genes of miR-141, miR-200b and miR-205. 
679, 666, and 508 genes are predicted to be direct target genes of miR-141, miR-200b, and 
miR-205, respectively. Among these, 99 genes are predicted to be direct target genes of 
both miR-141 and miR-200b, but only 13 out of these 99 genes (13.1%) are predicted to 
be direct target genes of miR-205. 
Table A.4. miRDB predicted target genes of miR-141, miR-200b and miR-205. 759, 
757, and 269 genes are predicted to be direct target genes of miR-141, miR-200b, and miR-
205, respectively. Among these, 104 genes are predicted to be direct target genes of both 
miR-141 and miR-200b, but only 8 out of these 104 genes (7.7%) are predicted to be direct 
target genes of miR-205. 
Table A.5. Gene expression profiles of the 16 gene panel of canonical EMT genetic 
markers in HEY cells after transfection of si-NC, si-ZEB1, si-WNT5A, or si-ZEB1-
WNT5A for 48 hours. Gene expression profiles are normalized and log2 transformed 
using RMA method. 
Table A.6. EMT/MET associated target genes of miR-200 family members (miR-141, 
miR-200b) and miR-205. miR-141, miR-200b target 20, 28 EMT/MET associated genes, 
whereas miR-205 targets 18 EMT/MET associated genes. 
Table A.7. EMT/MET associated target genes of miR-200 family members (miR-
141/200b) and miR-205 in human and mouse. miRNA target predictions of human and 
mouse were downloaded from microRNA.org. To reduce false positive results, only the 
predicted targets with mirSVR score < -0.1 were included. 
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APPENDIX B. SUPPLEMENTARY DATA FOR CHAPTER 3 
Table B.1. Gene expression profiles of un-transfected and transfected (miR-NC, miR-
203a, miR-205, and miR-429) HEY, SK-OV-3, and PC-3 cells. 
Table B.2. miRNA-mediated de-repression of repressor genes overrides expected 
down-regulatory effects of miRNA in HEY cells. 
Table B.3. miRNA-mediated de-repression of repressor genes overrides expected 
down-regulatory effects of miRNA in SK-OV-3 cells. 
Table B.4. miRNA-mediated de-repression of repressor genes overrides expected 
down-regulatory effects of miRNA in PC-3 cells. 
Table B.5. List of 84 genes that have been previously implicated to be important in 
the regulation of EMT/MET process. 
Table B.6. Genes targeted by the over expressed miR-203a that displayed changes in 
levels of expression consistent with the miRNA-induced changes in morphology and 
correlated EMT scores. 
Table B.7. Genes targeted by the over expressed miR-205 that displayed changes in 
levels of expression consistent with the miRNA-induced changes in morphology and 
correlated EMT scores. 
Table B.8. Genes targeted by the over expressed miR-429 that displayed changes in 
levels of expression consistent with the miRNA-induced changes in morphology and 
correlated EMT scores. 
Table B.9. miR-203a and miR-205 target binding site sequence comparison between 
SK-OV-3 and PC-3 cells. 




APPENDIX C. SUPPLEMENTARY DATA FOR CHAPTER 4 
Table C.1. Gene Symbol, Probe Set ID, and normalized expression value of the 18,643 
genes (19867 probe sets) detected in POC and MOC samples.  
Table C.2. Gene Symbol, Uniport Reference Number, protein annotation, and fold 
change of 4436 genes (4460 isoforms) identified (FDR < 0.01) in POC and MOC 
samples by mass spectrometry. 
Table C.3. Integration of the microarray and mass spec profiles identified 4436 genes 
found in both datasets. 
Table C.4. GeneGO biological pathways significantly enriched (p < 0.05) among genes 
differentially expressed between the POC and MOC samples on mRNA levels. 
Table C.5. GeneGO biological pathways significantly enriched (p < 0.05) among genes 
differentially expressed between the POC and MOC samples on protein levels. 
Table C.6. miRNAs and their target genes in the NC-D group (FC = 1.5). 
Table C.7. Differentially expressed (p < 0.05 and FC > 1.5) miRNAs and their target 
genes in the NC-D group. 
Table C.8. Up-regulated (p < 0.05 and FC > 1.5) miRNAs in the MOC sample and 
their target genes in the NC-D group (FC = 1.5). 
Table C.9. Up-regulated (p < 0.05 and FC > 1.5) miRNAs in the MOC sample and 
their targets in D-D group (FC = 1.5). 
Table C.10. Up-regulated (p < 0.05 and FC > 1.5) miRNAs in the MOC sample and 
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